ALBANY COLLEGE OF PHARMACY A N D H E A LT H SCIENCES PRESIDENT’S REPORT
24
23
1
2
16
17
18
19
20
21
22
15
11
14
12
13
HOW WE WILL
“A T H R I V I N G A C P H S C L A I M S T H E S PA C E AT THE INTERSECTION OF THE BASIC SCIENCES, CLINICAL SCIENCES, A N D P O P U L AT I O N H E A LT H S C I E N C E S .”
G R E G D E W E Y, P H . D . PRESIDENT
AC P H S P RE SID E N T’ S RE P O RT 1
THRIVE
TH E S E A R E C H A LLE N G I N G TI M E S FO R CO LLE G E S A N D U N I V E R S ITI E S .
The combination of rising operational costs and anemic enrollment growth have forced many schools to take actions that a few years ago were unthinkable. These range from workforce reductions to the elimination of academic programs and, in some cases, mergers or closures. At ACPHS, we are fortunate to have a tradition of fiscal control that gives us a strong foundation to withstand the current pressures on academia. We also are fortunate to have a history of student success that presents our students with strong career opportunities and has led to ACPHS graduates earning salaries that are currently ranked third highest in the country on the College Scorecard. We are, however, not immune to the forces reshaping higher education. As we determine the path forward in this increasingly competitive landscape, it is not sufficient to consider how we will survive as an institution. Rather, we must think instead about how we will thrive. This is an especially opportune time for us to consider how we move to the next level. The basic sciences continue to move forward at an unprecedented pace, expanding our knowledge of human biology at the biochemical, cellular, and organismal levels. The growth of our knowledge on complex disease states continues unabated. The historic advances in the basic sciences come at a time when we are also seeing an incredible impact of technology on the clinical and population health sciences. Medical devices and diagnostics are being developed that can monitor the physiological state of a patient in real-time, providing a comprehensive snapshot of an individual’s state of health. These developments, in combination with a deeper understanding of genomics, are accelerating the mainstream
adoption of precision medicine. Rapid genotyping technologies are bringing the promise of pharmacogenomics (tailoring a therapy to an individual’s genetic makeup) within reach. Information technology and informatics are also ushering in a new era in population health sciences where electronic health records can be mined to better understand the efficacy of treatments over large patient populations. But these big data approaches can do more than give us insights into efficacy. They can also introduce economics into the process and ultimately help determine how to balance the best therapy with cost effectiveness. These are not short term trends that will quickly fade away. The future of medicine and health care practice will be driven by the integration of the basic sciences, clinical sciences, and population health sciences. To be successful, our students must experience coursework and a research environment that integrates all three into robust programs of study. In the following Report, you will find articles highlighting people, projects, and programs that are advancing us in this direction. You will also “listen in” on a roundtable discussion about cancer that illustrates how knowledge from each of these core areas contributes to our understanding of this complex disease and our pursuit of a cure. So what does a thriving ACPHS looks like? It is an institution that claims the space at the intersection of the basic sciences, the clinical sciences, and the population health sciences – both in terms of research and education. We are educating the next generation of health care problem solvers, and we need to equip them with the tools for success. We are looking to thrive in an evolving health care and health science environment, and this requires that we embrace a future where we integrate basic, clinical, and population sciences.
CHIP OFF THE
OLD BLOCK
“ B E I N G AT AC P H S , I FEEL LIKE I HAVE RETURNED TO MY ROOTS IN THE PHARMACEUTICAL S C I E N C E S .”
BA S IC S CIEN CES AC P H S P RE SID E N T’ S RE P O RT 3
LI K E M A N Y S O N S W ITH R E B E LLI O U S S TR E A K S , J I M GA LLO, PH . D. was determined not to follow in his father’s footsteps. And as often happens in these scenarios, dad had the last laugh. Sort of. Dr. Gallo is Professor and Chair of the Albany Campus’ Department of Pharmaceutical Sciences. He joined the College in 2016 following stops at a number of high profile universities and research institutes, but his path here was anything but predictable. He grew up in Wisconsin where his father owned and operated Gallo’s Pharmacy. He spent a lot of time in the pharmacy where he helped out as a stock boy and ran errands, but he never envisioned a career for himself in pharmacy. He would eventually enroll as a student at the University of Wisconsin, but after three years he decided it was time for a change. He had accumulated 90 credits, including an impressive number of courses in math and science, but he felt like he was “drifting.” “I had piled up all of these credits, but practically speaking, I didn’t have a major. I knew what pharmacy was about, and I thought that might give me the focus I was seeking. I had a friend who went to Boston College, so I decided to move to Boston and enroll at Massachusetts College of Pharmacy.” After earning his pharmacy degree, he returned home to work in his father’s pharmacy. But he couldn’t shake the idea of pursuing a career in clinical pharmacy after “catching the bug” as a student at MCP.
He found that at Fox Chase Cancer Center in Philadelphia where the seeds would be sown for the rest of his career work. “At the time, there were 70 primary investigators working at the Center. I had my own grants, but I was also able to collaborate with physicians doing phase one clinical trials. It was the ideal environment for a young researcher like myself.” While working at the University of Georgia, Dr. Gallo had collaborated with a faculty member on a number of grants related to anti-HIV drug research. “One of the concerns about anti-HIV drugs is do they get into the brain. I started to become more interested in this area, and since I was working in a cancer center, I thought I should also be studying brain tumors,” he says. He subsequently did a sabbatical with a brain tumor doctor at Northwestern University, and he has largely dedicated himself to the study of brain cancer ever since, having completed three NIH grants in this area in the past four years. Dr. Gallo’s research utilizes a number of the same assays that are used for drugs for other cancers, but he also screens for blood-brain barrier penetration, a critical factor in the efficacy of brain cancer drugs. “If we have a promising drug, we do a pre-clinical model in a mouse to look at the pharmacodynamics and pharmacokinetics. Unlike many other programs, we then scale our models to humans and make predictions as to how the drugs may behave in the body and which patient populations are most likely to benefit from the drug. This is a form of precision medicine.”
He enrolled at the University of Florida, one of the few schools at the time to offer a Doctor of Pharmacy program, which existed then only as a post-baccalaureate option. He quickly fell under the wing of some faculty members doing research in pharmacokinetics. Almost immediately something clicked for him. “I knew in my first year at Florida that I wanted to do my Ph.D. in this field,” he says.
Of course, as department chair, he must balance his research projects with his other responsibilities as the leader of a ten person (and growing) department. “I’m working to create an environment that provides faculty with the time and resources they need to develop their research programs. As their research flourishes, that will also mean more opportunities for students in our bachelor’s and master’s programs in Pharmaceutical Sciences,” he says.
That’s exactly what he did, earning his Ph.D. in pharmacokinetics from the University of Arizona before heading to the University of Georgia as an Assistant Professor. It proved to be a good entrée point into academia, but he left after seven years in pursuit of a more research intensive environment.
There’s also the matter of recruiting new faculty and managing the other administrative tasks that come with the position. It’s a full plate, but he doesn’t seem to mind. “Being at ACPHS, I feel like I have returned to my roots in the Pharmaceutical Sciences,” he says. No doubt his father would be proud.
RESEARCH I F YO U A R E A S C I E NTI S T D O I N G R E S E A RC H O N H U M A N H E A LTH , your number one target for funding is likely the National Institutes of Health (NIH). NIH is the largest public funder of biomedical research in the world, but NIH supported grants are also the most competitive. NIH received 54,220 research project grant applications in fiscal year 2016, with the overall success rate for funding being less than 20%. Due to the volume of applications and the comparative scarcity of funding dollars, all grants submitted to NIH undergo a demanding peer review process. The first level of review is carried out by a Scientific Review Group composed primarily of non-federal scientists. The second level of review is typically performed by the relevant Institute and Center National Advisory Councils (NIH is made up of 27 Institutes and Centers), but in some instances, NIH may rely on boards made up of scientific and public representatives. The rigor associated with the review process means that NIH grants not only carry with them a level of prestige, they serve as validation for the quality and importance of a given research project. So when two ACPHS faculty members – Associate Professor Meenakshi Malik, Ph.D., and Assistant Professor Tim LaRocca, Ph.D. – were each awarded $480,000 NIH grants within a three-week span in December 2016, it marked an extraordinary accomplishment for the College. It was made even more noteworthy by the fact that Drs. Malik and LaRocca are both members of the same department, the Department of Basic and Clinical Sciences. The greatest beneficiaries of these grants, however, may be ACPHS students, particularly those in the Bachelor’s
program in Microbiology and the Master’s program in Molecular Biosciences. That is because both grants, which are categorized by NIH as R15’s, come with the requirement that the principal investigators use the funding to help “expose students to research.” Dr. Malik’s grant is the renewal of a previously funded NIH grant. It will allow her to continue her study of Francisella tularensis, a deadly bacterium that has been classified by the Centers for Disease Control as a Category A bioterrorism agent. Mentoring students is nothing new for Dr. Malik; she has a long history of integrating students into her lab. Over the three-year period of her previous NIH grant, she authored six publications in peer reviewed journals that included Molecular Microbiology and the Journal of Biological Chemistry. Five different ACPHS undergraduate and graduate students were named co-authors on these publications. Dr. LaRocca joined the College in January 2015, and this represents his first NIH grant. The focus of his project is to gain a deeper understanding of the process by which red blood cells die, and with this knowledge, work to improve treatments for patients suffering from bacterial blood infections and other blood related disorders. Dr. LaRocca already had ACPHS students working in his lab, and this NIH grant will enable more students to gain meaningful research experience at both the undergraduate and graduate levels. As the College continues to build out its capabilities in the Basic Sciences, grants such as these will play a critical role in supporting those efforts while also providing excellent opportunities for students to engage in cutting edge research.
BA S IC S CIEN CES AC P H S P RE SID E N T’ S RE P O RT 5
AND DEVELOPMENT
MEENAKSHI MALIK’S A N D T I M L A R O C C A’ S N E W NIH GRANTS WILL HELP T R A I N T H E N E X T G E N E R AT I O N OF RESEARCH SCIENTISTS.
TWO DEGREES ARE
BETT F O R S T U D E N T S S E E K I N G TO D I F F E R E NTI ATE TH E M S E LV E S in the eyes of future employers and graduate schools, a master’s degree is an excellent option. Albany College of Pharmacy and Health Sciences introduced its first master’s degree program in the late 2000’s and now offers five such programs. Each one has been developed as a complement to, or extension of, an existing undergraduate program(s) which means that there are a number of intentional synergies that exist between the various B.S. and M.S. programs. ACPHS has made the pursuit of a master’s degree easier through the availability of four dual degree programs. Dual degree programs allow students to receive a bachelor’s and master’s degree in five years instead of six – a structure that helps them save both time and money as they prepare for the next step in their careers.
The newest of the College’s dual degree programs was introduced in February 2017. It combines a Bachelor’s in Microbiology and a Master’s in Molecular Biosciences. This dual degree offering has been designed to provide students with a stronger foundation in research, and includes a research rotation in Year 4 followed by a written thesis and defense in Year 5. By attending just one extra year of school, dual degree graduates gain a competitive advantage that will not only provide a boost to their immediate post-graduate plans, but may also be viewed favorably as they seek to advance their careers in the future. It’s a combination that is tough to beat which is why an increasing number of students are being drawn to these programs.
BA S IC S CIEN CES AC P H S P RE SID E N T’ S RE P O RT 7
TER
THAN ONE
DUAL DEGREE PROGRAMS AT ACPHS n
.S. in Biomedical Technology / B M.S. in Cytotechnology and Molecular Cytology
n
.S. in Biomedical Technology / B M.S. in Clinical Laboratory Sciences
n
.S. in Pharmaceutical Sciences / B M.S. in Pharmaceutical Sciences
n
.S. in Microbiology / B M.S. in Molecular Biosciences
8 ACP H S
P R ESI DENT’ S R EPORT
BRIDGING THE DIVIDE
“WE NEED TO GET MORE P E O P L E FA M I L I A R WITH THE SKILLS AND K N OW L E D G E T H AT P H A R M A C I S T S P O S S E S S .”
CLIN ICA L S CIEN CES AC P H S P RE SID E N T’ S RE P O RT 9
O N A N Y G I V E N DAY, A S S O C I ATE PRO F E S S O R O F PH A R M ACY PR AC TI C E K ATI E C A R D O N E , PH A R M . D., B C AC P,
doubts, but by the end of my third semester in the program I had developed a real interest in nephrology.”
may be found working with chronic kidney disease patients, conducting medication therapy management consultations, developing online courses for the College’s nephrology concentration, publishing articles, delivering presentations, precepting students, and more. All of which makes it hard to believe that it took three years of school to convince her that pharmacy was the right career choice.
Following graduation, she did a two-year fellowship in nephrology with Dr. Harold Manley, a former ACPHS faculty member. “The fellowship was the synthesis of my previous experiences in community pharmacy, nephrology, and research. It combined everything that I enjoyed doing. It’s what ultimately led me to academia because I saw it as the best opportunity to continue my involvement in all of these aspects of pharmacy.”
“I had been asked by my high school guidance counselor to consider pharmacy, but at the time, I was leaning towards engineering. My image of what a pharmacist did was the shopkeeper in the Norman Rockwell painting. That wasn’t something that appealed to me, which is why ACPHS was the last school I visited when I was looking at colleges,” she says. But when she arrived on campus, she found herself attracted to the close-knit feel of the College and the strong focus on science, which is a hallmark of the pre-pharmacy curriculum. She decided to enroll. Despite positive early experiences at the College, she considered transferring after each of her first two years. Everything changed after her third year when she began working as a pharmacy intern at Price Chopper. “I really enjoyed the opportunity to work with patients in a community setting. It was also interesting to watch the transition between basic sciences and clinical applications play out in the pharmacy. I liked that bridge.” From that point on, there was no turning back. With her commitment to ACPHS and her career path now solidified, Dr. Cardone immersed herself in the College and her future profession. She joined the soccer team, worked in the research lab of Professor Bob Levin, and applied for the Early Patient Oriented Care (EPOC) program, which is where she developed her interest in nephrology. “Before starting the program, students were asked to rank the areas of interest to them. I put dialysis last on the list, and, of course, that’s where I ended up,” she laughs. “[Professor] George Bailie said to me, ‘It’s a good character builder to get up at 6 am and go to dialysis.’ I had my
Fast forward to the present day and Dr. Cardone is now mentoring her own post-graduate trainees. She started a nephrology pharmacy residency two years ago – one of only two such residencies in the country – and recently received accreditation by the American Society of Health-System Pharmacists (ASHP). She is also using her research as a platform to bridge (there’s that word again) pharmacy with other fields such as Public Health. One such project is a collaboration with Associate Professor Wendy Parker in the ACPHS Department of Population Health Sciences. The two are exploring the impact of pharmaceutical care services such as medication adherence and health literacy on the outcomes of patients suffering from chronic kidney disease. The collaboration has resulted in external grant funding a nd academic publications. For someone who once had to be sold on the profession of pharmacy, Dr. Cardone has emerged as one of its strongest advocates and a role model for future pharmacists. She believes that the profession has just scratched the surface of its potential, and she hopes to see its profile further elevated in the eyes of the public. “Within our own profession, we know that we are valuable members of the health care team. But much of the public does not know about the pharmacist’s education or what they do beyond dispensing. Even within the health care team, we need to get more people familiar with the skills and knowledge that pharmacists possess,” she says. “If we are not vocal about our capabilities and contributions, how will anybody know?”
B R E AT H I N G
S C H E N E C TA DY CO U NT Y I S BAT TLI N G A N A S TH M A PRO B LE M , and the Asthma Coalition of the Capital Region is looking to ACPHS, and specifically its students, for assistance. According to the latest data from the New York State Department of Health, Schenectady County ranks 4th among 57 counties in the state (excluding New York City) with 78.1 asthma emergency department visits per 10,000 residents. Following the 2016 opening of College Hometown Pharmacy in the Hometown Health Centers clinic in Schenectady, the Asthma Coalition of the Capital Region (ACCR) approached the College for help with its efforts to improve asthma care. ACPHS Assistant Professor See-Won Seo explains the challenges inherent in asthma treatment: “There is so much that needs to be covered related to asthma devices and medications, and the provider doesn’t always have the time to walk through everything with the patient. Having a pharmacist available to follow up and ‘close the loop’ can go a long way towards improving outcomes with asthma patients.” Through the partnership with ACCR, student pharmacists from the College who rotate through Hometown Health Centers now receive daily reports to help identify patients in the clinic who may benefit from additional asthma counseling. Indicators flagged in these reports may include one or more of the following: ecent asthma-related ER visits or hospitalizations R A sthma Control Test score ≤ 19, indicating poor control n F ailure to pick up controller asthma medications from the pharmacy n E xcessive refills of a rescue inhaler from the pharmacy n n
Once a patient is identified, the students meet with the patient after regularly scheduled appointments with their provider to review their medications and ensure the patient knows how to properly use their device(s). As part of the meeting, students demonstrate for each patient how their device works and then watch to see that the patient is using it properly. The students also provide disease state education, asthma action plans, and trigger avoidance/identification. Since the program has started, they’ve already noticed instances where providers have increased dosing when, in fact, the problem stemmed from the patient not taking the medicine correctly. “The area where we feel there is the most opportunity for rapid improvement is with the development or update of a patient’s Asthma Action Plan,” says ACPHS Assistant Professor Jacqueline Cleary, whose practice site is in the Hometown Health Centers clinic. “What are the medications they should and should not be taking? When should they know to increase their albuterol based on their symptoms? When is the right time to call the doctor or seek emergent care? Our job is to make sure they know the answers to these questions.” As the program continues to grow, the College plans to integrate 10-15 pharmacy students in their second professional year (P2) to assist with asthma education. When these students become P3’s, they will train a new class of P2’s and that cycle will be repeated each year. Dr. Seo would eventually like to see students receive permission to visit patients’ homes and shadow Healthy Neighborhoods Program professionals. “Pharmacists tend to focus on the medications which can cause them to overlook factors in the patient’s home environment that may be exacerbating their asthma such as smoking or pet dander. When it comes to asthma care, it is important to understand the big picture so that you can ask the right questions and direct the patient to the most effective resources.”
CLIN ICA L S CIEN CES AC P H S P RE SID E N T’ S RE P O RT 11
EASIER AC P H S S T U D E N T S AT COLLEGE HOMETOWN PHARMACY ARE LEARNING HOW THEY CAN H E L P R E D U C E T H E I M PA C T OF ASTHMA ON RESIDENTS O F S C H E N E C TA D Y C O U N T Y.
DE
CLIN ICA L S CIEN CES AC P H S P RE SID E N T’ S RE P O RT 13
MAND ON THE RISE
F O R L A B O R AT O R Y PROFESSIONALS
I N TH E F I E LD O F H E A LTH C A R E , M U C H time is spent discussing and analyzing treatment. What is the best course of therapy? Is the patient capable of adhering to the therapy? Is the prescribed therapy the most cost effective option? But before any conversation can take place about how to best treat a patient, there first needs to be a diagnosis, and in approximately 70% of situations, a patient’s diagnosis is determined after consulting the results of a laboratory test(s). Advances in technology over the past two decades have greatly expanded the range of tests available to providers. There are now approximately seven billion diagnostic tests performed each year in the United States alone! As the amount and sophistication of these tests have grown, the need for clinical laboratory science professionals to evaluate and interpret the results has increased proportionately. Yet, despite these
developments, the number of academic programs for laboratory professionals has been declining since the early 1990’s. The nation’s labs need to fill more than 7,000 jobs annually, but U.S. clinical laboratory education programs are producing approximately 5,000 qualified laboratory professionals each year. The math is pretty simple. Every graduate from an accredited program is going to have a job offer, and in some cases, multiple offers. As ACPHS looks to the future, its continuing commitment to the laboratory sciences (the College offers both B.S. and M.S. degrees in Clinical Laboratory Sciences, in addition to an M.S. in Cytotechnology and Molecular Cytology) positions it well to help address an important need in the nation’s health care system while providing opportunities for students in a field with excellent career prospects.
C U LT U R E OF OPPORTUNITY
“ C U LT U R E S DON’T JUST HAPPEN. THEY ARE F O R M E D .”
P O P U LAT IO N H EA LT H S CIEN CES AC P H S P RE SID E N T’ S RE P O RT 15
WA LK I NTO TH E O F F I C E O F CO LLE E N M C L AU G H LI N , PH . D. , and certain things strike you immediately – an array of multi-colored post-it notes affixed to the wall, figurines of a tortoise and hare placed conspicuously on her desk, and a sign that says, “Culture eats strategy for lunch.” Dr. McLaughlin joined the College in February 2017 as the founding chair of the Department of Population Health Sciences. Prior to coming to ACPHS, she spent 25 years at the New York State Department of Health (DOH) where she worked in multiple bureaus of the department including the Bureau of Sexually Transmitted Disease Prevention and Epidemiology, the Office of Primary Care and Health Systems Management, the Bureau of Chronic Disease Epidemiology and Surveillance, and the Bureau of Cancer Epidemiology. The Department of Population Health Sciences was formed in spring 2016 as part of a strategic realignment for the College. “We created the department to help facilitate collaborations between the School of Pharmacy and Pharmaceutical Sciences and the School of Arts and Sciences,” explains ACPHS Provost Tarun Patel, Ph.D. “In addition to the six core faculty members in the department, there are three faculty members with joint appointments, and we anticipate that number will grow. These interschool and inter-disciplinary collaborations are going to help advance teaching and research at the College and ultimately enrich the academic experiences of students across all of our programs.” As the founding chair, Dr. McLaughlin will play a key role in building the department and helping establish its identity. She’s more than up to the task. “I strongly believe that cultures don’t just happen, they are formed,” she says. “It starts with how people treat each other, how they communicate, and how they lead. It’s important to me that the faculty members here feel like they are part of a community, not simply members of a department.” “That’s the reason for the ‘Culture Eats Strategy for Lunch’ sign. If you don’t have the right culture in place, even the best strategies are destined to fail.” The Department of Population Health Sciences is home to the B.S. in Public Health (introduced in 2016) and the M.S. in
Health Outcomes Research and Informatics, two programs with natural synergies that haven’t been fully tapped. “Prior to my arrival, the faculty did an excellent job of developing and launching these two academic programs, which are still relatively new,” says Dr. McLaughlin. “I’m looking to build upon the foundation they have established by adding what I have learned through my experiences in the workplace. Together, we will ensure that our students graduate with the skills needed to excel in the field of public health.” Which leads us back to those post-it notes. These represent the vision for a revamped Public Health curriculum, one that expands the range of coursework while still enabling students to specialize in their areas of interest. One of the new courses will be a Seminar in Public Health, a course for juniors that Dr. McLaughlin will teach this fall. “I have always enjoyed working with students. I taught epidemiology in SUNY Albany’s School of Public Health for seven years, and I planned to do more teaching after I retired,” she says. “Now I have an opportunity to do it sooner!” In addition to revisiting the curricula of the Public Health and Health Outcomes programs, Dr. McLaughlin is working with faculty to codify a research agenda for the department. “Our research vision for the department must be one that aligns with President Dewey’s vision for the College,” she says. “Making these linkages between our work and the strategic goals of the institution has been a fun exercise for us and something that I really enjoy.” With so much to do for the naturally energetic McLaughlin, it can be difficult to know where to start. Enter the tortoise and the hare. They serve as reminders of the book Thinking Fast and Slow by Nobel Prize winner Daniel Kahneman. The book explores the forces that govern our thoughts and actions, helping determine when a quick decision is needed and when more deliberate thought is advised. Looking ahead, Dr. McLaughlin has no shortage of ideas for the department including plans to develop a five-year dual degree program in Public Health and Health Outcomes and exploring opportunities to offer continuing education programming for public health professionals. But that’s a whole other set of post-it notes.
AN OUNCE OF
A 2 0 1 5 A RTI C LE F RO M TH E J O U R N A L PATI E NT PR E F E R E N C E A N D A D H E R E N C E states that an estimated half of chronic disease medications are not taken as prescribed. Worse yet, studies have linked non-adherence among sufferers of chronic diseases to poorer treatment outcomes and the progression of disease symptoms and complications. When the disease is type 1 diabetes mellitus (T1DM) and the patient is an adolescent, the consequences of nonadherence can be life altering. Complications from poorly controlled, long-standing T1DM include heart disease, eye damage, pregnancy complications, and kidney disease. Persistent non-adherence beginning in early adulthood can lead over time to the early onset of these conditions. Associate Professor of Population Health Sciences Wendy Parker, Ph.D., and Associate Professor of Pharmacy Practice Katie Cardone, Pharm.D., BCACP, want to prevent such scenarios from taking place. The two faculty members, along with ACPHS students from the Public Health and Pharm.D. programs, are collaborating on a project that seeks to identify the risk factors that may inhibit successful medication self-management among adolescents suffering from T1DM. Since T1DM (sometimes referred to as Juvenile Diabetes) is usually diagnosed in childhood, parents or other caregivers naturally play a significant role in managing the child’s medications. Responsibilities may include obtaining diabetic supplies, administering medications, managing nutrition, obtaining medication-related information, recognizing medication problems, and negotiating insurance plans. Parents begin to play a lesser role in medication-related care as T1DM children move into adulthood, and it is during this transition where the threat of non-adherence increases.
Many young adults struggle in particular when they leave home for the first time (e.g., to go away to College) and have to shoulder more of the responsibilities for their own health. But which adolescents are most at risk and what types of interventions can help avoid adverse health events? Exploring these questions will be the focus of the project, which is being supported by a grant from The John Faunce and Alicia Tracy Roach Fund and administered by the Community Foundation of the Capital Region. For the initial phase of the project, Drs. Parker and Cardone will be partnering with the local chapter of the Juvenile Diabetes Research Foundation (JDRF) to do one-on-one interviews with adolescent T1DM patients and parents. Following the interviews, the research team will then compare the findings with data available in the T1D Exchange Registry, a repository containing clinical, laboratory, and patient-reported data from over 28,000 patients across 75 U.S.-based health clinics. Using mathematical modeling, Drs. Parker and Cardone will seek to isolate potential risk factors for non-adherence across different patient profiles. As Dr. Parker notes, identifying the risk factors is only part of the solution. “Then the challenge becomes, how do you craft the messages to help bring attention to these risks? How does this population want to receive those messages? How do you get them to trust you? It is a lot to consider which is why getting perspectives from multiple disciplines is often needed to determine the best way to attack the problem.” Adds Dr. Cardone, “The ultimate goal of the project is to encourage proper self-management of medications for these adolescents and prevent long term, negative health consequences that may result from non-adherence.”
P O P U LAT IO N HEA LT H S CIEN CES AC P H S P RE SID E N T’ S RE P O RT 17
PREVENTION C O L L A B O R AT I V E P R OJ E C T SEEKS TO REDUCE THE RISKS OF NON-ADHERENCE I N Y O U N G A D U LT S W I T H TYPE 1 DIABETES.
P U B L I C H E A LT H F O R T H E
PUB
P O P U LAT IO N HEA LT H S CIEN CES AC P H S P RE SID E N T’ S RE P O RT 19
LIC
GOOD
TH E BAC H E LO R ’ S PRO G R A M I N PU B LI C H E A LTH is the latest undergraduate degree offering from the College, having received approval from the New York State Office of Higher Education in spring 2016.
an aspect of public health that aligns with their career interests.
The Public Health program evolved from the College’s B.S. program in Health and Human Sciences (HHS) which launched in 2009. The Public Health program expands from the core HHS program to integrate a wider variety of coursework in areas that include social science, applied science, epidemiology, statistics, and research.
“As a college centered around human health, the addition of a Bachelor’s program in Public Health is a natural extension of our academic offerings,” says Associate Professor Wendy Parker, Ph.D., who serves as the Director of the Public Health program. “By leveraging our collective strengths as an institution, we have created a true interdisciplinary program that educates students to become scientifically grounded and socially engaged.”
The B.S. in Public Health curriculum – which is based on the accreditation standards published by the Council on Education for Public Health – requires students to select one of two tracks: Community Health or Health Analytics. Each track culminates with a capstone project (typically an internship or research project) in which students focus on
The Bureau of Labor Statistics also sees great opportunities in the field of Public Health. Their employment forecast for Public Health and related areas states, “Growth will be driven by efforts to improve health outcomes and to reduce health care costs by teaching people about healthy habits and behaviors and utilization of available health care services.”
THE
WA R TO E N D A LL WA RS
W H E N PR E S I D E NT R I C H A R D N I XO N signed the National Cancer Act on December 23, 1971, it kicked off what became popularly known as the “War on Cancer.” It’s been nearly 50 years since the bill became law, and while progress has undoubtedly been made in the search for better treatments and outcomes, it quite likely has fallen short of the expectations of those who enacted the legislation. Cancer remains the leading cause of death worldwide and is second only to heart disease in the U.S. According to the National Cancer Institute, approximately 39.6% of men and women will be diagnosed with cancer at some point during their lifetimes. That’s 2 out of every 5 people walking the planet.
But there are also encouraging signs. From 2004-2013, the overall cancer death rate in the United States fell by 13% as the number of cancer survivors increased. The number of people in the United States living beyond a cancer diagnosis reached nearly 14.5 million in 2014 and is expected to rise to almost 19 million by 2024. Yet, each piece of good news seems to be followed by one that casts doubt on our progress against this relentless disease. So where are we making the most gains? Where are we falling behind? Is a cure possible someday, and for that matter, what does a cure even look like? For insights to these and other questions, we gathered a roundtable of ACPHS faculty from the basic sciences, clinical sciences, and population health sciences to share their perspectives on the state of cancer care today and what the future may have in store.
CA N CER R O U N DTA BLE AC P H S P RE SID E N T’ S RE P O RT 21
JENNA LEBLANC D IRECTOR, M.S. P RO G RAM I N CYTOTECH NOLOGY AN D M O LE C U LAR CYTOLOGY
ALLISON M. BURTON-CHASE AS S I STANT PROFESSOR, DE P T. OF POP U L AT I ON H EA LTH SCIE N C E S
SHAKER MOUSA CH A IR M A N A N D E X E CUT IV E V P, P H A R M ACE UT ICA L R E S E A R CH IN S T IT UT E
TA R U N B . PAT E L P R OVO S T
S T E FA N B A L A Z
S A R A H S C A R PA C E P E T E R S
CH AIR, DEPT. O F P HARM AC E U T I CAL SC IENC ES, VE RM O N T CAM P U S
A S S O CIAT E P R O F E S S O R , D E P T. O F P H A R M ACY P R ACT ICE
22 CA N C E R
R OUNDTABL E AC PH S PRE SID E N T ’S RE PORT
THE CANCER DEATH RATE – ADJUSTED FOR AGE AND SIZE OF THE POPULATIO N – FELL JUST FIVE PERCENT BETWEEN 1950 AND 2009. DURING THIS SAME PERIOD, THE DEATH RATE FROM HEART DISEASE FELL BY NEARLY TWO-THIRDS. WHAT IS IT ABOUT CANCER THAT MAKES IT SO DIFFICULT TO TREAT? PATE L: Here’s the problem. We have 25,000 genes in our bodies – many of which are involved in cancer. You can identify and block certain cancer targets to effectively create a traffic jam, but the cancer cells are highly adaptive, and they know how to maneuver through the traffic. Cancer is like an aggressive driver who finds a back alley to get around the problem. When it heads down one of these alleys is when it’s very hard to treat. MOUSA: This is an opportunistic disease. Tumors operate independently in the body. If there are enough cancer cells, they are able to evade the immune system and build their own blood supply network. This is what allows the cancer to grow and spread, and that is when it becomes difficult to control.
PETERS: I feel that statistic is a bit misleading. Survival rates for some types of cancer have improved significantly through the years. Chronic Myeloid Leukemia (CML) is a great example. As a result of new oral targeted therapies that were approved in the early 2000’s, CML patients are now living nearly as long as non-CML patients.
BURTON-CHASE: I would add that part of the problem is the language that we use. We talk about cancer as if it is a single entity, but cancer is an umbrella term for more than 100 different diseases. The more we learn, the more we realize how complicated it is.
THERE ARE THREE BASIC WAYS TO COMBAT CANCER: PREVENTION, DETECTION, AND TREATMENT. WHICH OF THESE AREAS HOLDS THE MOST PROMISE IN THE COMING DECADE FOR NOTABLY IMPACTING SURVIVAL RATES? PATE L: I would say detection. If you can identify the type of cancer early, you can target the therapy better. This begins to move towards precision medicine.
B U RTO N - C H A S E : I think the best opportunities are on the prevention side. We know that 25-30% of cancer deaths are related to smoking. Another 20-25% are diet related. Some people in the field believe that as many of 90% of cancer deaths can be prevented with behavioral changes. We have put a lot of money into treatment, and we have not gotten the same returns as we have with effective prevention strategies.
PETE R S : I agree. The number of preventable cancer cases is much greater than the number of positive outcomes from any drug therapy currently on the market. LE B L A N C : Cancer is such a multi-factorial disease that I don’t think you can separate these areas. They need to work together. More education is certainly needed as far as prevention is concerned. I’m also a big advocate for screening, and improving the ways we do it, so that we can diagnose the cancer while there’s still time to treat it. PROVOST PATEL MENTIONED “PRECISION MEDICINE” WHICH IS A TERM WE HEAR A LOT ABOUT THESE DAYS. WHAT IS ITS POTENTIAL AND HOW WIDELY IS IT BEING USED TODAY IN THE TREATMENT OF CANCER PATIENTS? M O U SA : Cytotoxic chemicals used to treat most cancers are effectively poison, so you have to be very careful about how they are distributed throughout the body. I strongly believe that to effectively eliminate the tumor you have to surprise it. That means hitting it with a “big load” of chemotherapeutic drugs, perhaps 100x the concentration that we would normally use. The only way to do this without harming the patient’s normal organs is through precision medicine where you can harness the power of nanotechnology, for example, to target the tumor and minimize the spillover to the healthy cells and organs of the body. PETE R S : Some of the newer drugs are small molecules with very specific targets. They still affect normal tissue but not to the degree that you would expect to see when you think about the traditional cytotoxic chemo experience. Knowledge of pharmacogenomics is also being adopted in the treatment of cancer, which is helping us better target which drugs will be most effective in which patients. This is
CA N CER R O U N DTA BLE AC P H S P RE SID E N T’ S RE P O RT 23
not some futuristic concept – it is something that we are using today in the clinic.
care, and when there is a breakthrough, we tend to do a poor job of educating people about it.
BA L A Z: This is true. Pharmacogenomics is able to tell
LE B L A N C : Most people hear HPV and think “women”
us about factors such as the presence or absence of certain targets, transporters, or metabolizing enzymes, which can help us estimate whether a certain treatment is likely to be successful. However, there is a lot of space left between the basic pharmacogenomic information and what is taking place in the body. What is happening in the cell that changes its behavior to the type of uncontrolled growth we see in cancer? What are the differences between the drug-affected components of the cancer cell and a normal cell? This needs to be analyzed. Precision medicine takes into account knowledge about the kinetics of many different processes, but to harness its potential, we need to know more about the basic mechanisms at work.
and “cervical cancer.” However, HPV is also found in certain head and neck cancers. And it’s not just in females. It’s in males too. But that message does not always come through which underscores the fact that we are falling short on education.
THE 21ST CENTURY CURES ACT ALLOCATES NEARLY $2 BILLION FOR CANCER RESEARCH (THIS INITIATIVE IS REFERRED TO AS THE “CANCER MOONSHOT”). IF YOU WERE IN CHARGE OF THAT MONEY, WHAT TYPES OF INITIATIVES WOULD YOU INVEST IT IN? LE B L A N C : I’d like to see more money directed to the expansion of screening programs. If we can identify biomarkers for more types of cancers, it will help us develop better targeted and tailored treatment therapies. I’d also like to see research that explores the impact of screening at younger ages. Too often we look only when there’s a problem. That’s not a screening program; that’s a diagnostic program.
BA L A Z : There is still a great need for more basic science research into the mechanisms of cancer. The pharmaceutical industry rarely does this type of research, which means government support is critical to driving it, particularly in the early stages.
B U RTO N - C H A S E : I would invest more money in cancer education. We have a poor education system when it comes to cancer, and it is not just with the general public, but the providers as well. We have, for the first time ever, a preventive cancer vaccine (HPV). It is the only cancer vaccine that has ever been developed, yet we do not see the uptake rates that you see in other developed countries. All clinicians do not promote it in the same way. Some make it seem like a choice. We have not had a lot of major advances in cancer
IN OUR ONGOING BATTLE WITH CANCER, WHAT IS YOUR GREATEST CAUSE FOR HOPE? PETE R S : Seeing new classes of drugs coming to fruition and how our knowledge of the basic pathology of cancer is expanding are both reasons for optimism. That is translating to greatly improved survival in cases where we didn’t see it before. For example, when I was in residency, patients with Stage 4 lung cancer used to live six months, and now these patients can live as long as 2-5 years.
B U RTO N - C H A S E : I would say it is patients being advocates for themselves – being more proactive with their providers, sharing more information within families. They are on a much more level playing field than in the past, and better-educated patients typically get better treatment and have better outcomes.
LE B L A N C : We have made tremendous improvements in diagnostics and finding certain cancers earlier. There used to be sites in the body that were very difficult to access like the pancreas. Now endoscopic ultrasound can get to places that weren’t easily accessible before. Endobronchial ultrasound allows us to not only reach lesions in the respiratory tract, but also the surrounding lymph nodes, which helps determine staging. These techniques have really entered the mainstream in the past 10-15 years. The ability to make earlier and more accurate diagnoses has improved outcomes for countless numbers of patients because, in most cases, the earlier you find the cancer, the more effective the treatment will be.
M O U SA : The technological advances are remarkable. It is now about implementation and adoption. We need to find ways to accelerate the marriage between technology and practice.
24 CA N C E R
R OUNDTABL E AC PH S PRE SID E N T ’S RE PORT
WHAT GIVES YOU THE MOST CONCERN? PETE R S : I’m very concerned about prevention getting overlooked, particularly when I read reports that millennials have higher rates of colorectal cancer than Generation Xers and Baby Boomers. I’m also concerned by what seems to be increasing numbers of younger people getting diseases they shouldn’t have. There needs to continue to be epidemiological research to monitor these trends and help inform prevention efforts. PATE L: For me, it’s the shrinking levels of government research funding in the sciences. Right now, the National Cancer Institute (NCI) funds scored grants at around the six percentile. But it’s not only that. Not every approach for treating cancer comes from NCI-funded research. Continued cuts to NIH funding will mean research on other diseases will also suffer. Sometimes it’s a breakthrough in one area of study that fuels an advance in a different field. It’s very interconnected. M O U SA : I could not agree more. If we continue to reduce funding for scientific research, labs are going to shut down. There will be fewer new scientists. In fact, it’s happening now. When I talk to post docs today, they want to go into industry for administrative and management opportunities, not research-based faculty positions. The training and retraining that takes place in academia fosters collaborations. That would all get cut out. This would have decades and decades of deleterious effects on scientific progress and innovation. HOW DO YOU DEFINE A CURE IN THE CONTEXT OF CANCER, AND WHAT IS THE POSSIBLE TIMELINE FOR SUCH A CURE? B U RTO N - C H A S E : Instead of talking about a cure, we should really be talking about remission – for how long and for whom. Optimism is important, and you certainly do not want to take that away, but you have to balance patient expectations with reality. For example, when we talk about survival rates, we mean a certain type of cancer has, say, a 40% survival rate over the next five years. We do not systematically collect and discuss data for 10, 15, 20 years out. That is not always made clear to patients, which is why we need to do a better job of having these conversations. When patients and families get information after the fact, that is when they start to feel like the health care system does not work for them.
PETE R S : In the medical community, we define cure as good long term survival, but that’s not what patients want to hear or accept. People want to feel they can have control over their cancer, but it also contributes to this false sense of outcome. Patients will always ask me, “How long do I have to be on this therapy?” and I explain, “Until you have side effects you cannot tolerate or until it doesn’t work anymore.” It’s hard to have those conversations because sometimes patients think they will be able to take a pill for a month, and they will be cured. Based on what we know today, metastatic disease cannot be cured. You can’t get rid of it. But if you can manage it and keep it from spreading to vital organs, it could take on the shape of a chronic disease similar to how we now treat HIV. M O U SA : I agree with Sarah. If we can localize the cancer and control its behavior, we can treat it like a chronic disease. I think within a decade or two we can get there with many forms of cancer therpeutics. However, that assumes we have adequate government funding for research and are able to resolve some of the related bioethical issues. LE B L A N C : For me, a cure is about moving past a onesize-fits-all approach to care and getting the patient the type of individualized treatment they need.
BA L A Z : Any discussion of a cure must consider the type of cancer and how quickly it becomes mortal. A cure leads to a measurable extension of life. It’s hard to imagine for some types of cancer that we will cure them completely. Depending on the type of cancer, therapies may extend survival by 20 years or far less, but they are all beneficial.
PATE L: Five years of remission is a success, success, success. In remission, patients are checked regularly, and our monitoring continues to improve which means any future treatments are going to begin sooner and hopefully be more effective. PETE R S : If I could just add one more thing … It’s important to keep in mind that we all have the potential to develop cancer. We all have mutations in our DNA that our bodies are trying to fix and repair right now. Mutations accumulate in our genes, but we typically can handle them. Unfortunately some people are not able to manage it for reasons that may have to do with their immune systems, genetics, environmental exposure, or something else altogether. What that trigger is and why and when it occurs – that is the million dollar question.
CA N CER R O U N DTA BLE AC P H S P RE SID E N T’ S RE P O RT 25
T HE PANELI STS S TE FA N BA L A Z , PH . D. is the Chair of the Department of Pharmaceutical Sciences in the ACPHS-Vermont Campus. The goal of his research is to better understand the processes affecting the fates and effects of drugs in the body in terms of drug structures and properties.
A LLI S O N M . B U RTO N - C H A S E , PH . D. , is an Assistant Professor in the Department of Population Health Sciences. Her primary area of research is in the behavioral aspects of cancer prevention and survivorship in families with hereditary cancer syndromes.
J E N N A LE B L A N C , M . S ., C T ( A S C P) , is the Director of the Master’s in Cytotechnology and Molecular Cytology program. She also serves as the President of the American Society for Cytotechnology.
S H A K E R M O U SA , PH . D., M BA , is the Chairman and Executive Vice President of the Pharmaceutical Research Institute and Vice Provost of Research. His research explores ways that nanotechnology and biotechnology can be used to improve the detection, prevention, and treatment of cancer.
TA R U N B . PATE L , PH . D., is the Provost at ACPHS. He has received more than 30 externally funded grants, including 16 from the National Institutes of Health. The focus of his research is hepatocellular carcinoma, the most common form of liver cancer. S A R A H S C A R PAC E PETE R S , PH A R M . D., M PH , B CO P, is an Associate Professor in the Department of Pharmacy Practice and a board certified oncology pharmacist with a practice site at the St. Peter’s Health Partners Cancer Care Center. She is the immediate Past President of the Hematology/Oncology Pharmacy Association.
16
17
18
19
20
21
22
1
14
13
12
24 2
23 3
15
11
SSCH CHOOLA LARRLY LY ACT ACTIV IVIT ITYY RREP EPOORT RT AC P H S P RE SID E N T’ S RE P O RT 27
S C H O L A R LY
ACTIVITY
REPORT JANUARY 1, 2016 – DECEMBER 31, 2016
28 ACP H S
PR ESI DENT’ S R EPORT SC HOLA RLY AC TIV ITY REPORT
SCHOOL OF PHARMACY AND PHARMACEUTICAL SCIENCES D E PARTM E NT OF PHAR MACY PR AC TI CE PUBLICATIONS
Chemotherapy 2016 Apr
Pharmacy, 2016 Aug 3
Saroka RM, Kane MP,
Neely MN, Gulati A,
22;60(5):3170-3.
(ePub ahead of print).
Robinson L, Busch RS. No
Scheetz MH. Evaluation
postoperative adrenal
of Vancomycin Exposures
Monique Bidell Bidell MR, McLaughlin M,
Jo Carreno
Davis JM, Wegrzyn N,
insufficiency in a patient
Associated with Elevations
Faragon J, Morse C, Patel
Carreno JJ, Kenney RM,
Cardone KE. Sweetening
with unilateral cortisol-se-
in Novel Urinary Biomark-
N. Desirable Charac-
Divine G, Vazquez JA,
the deal: Effects of SGLT-
creting adenomas treated
ers of Acute Kidney Injury
teristics of Hepatitis C
Davis SL. Randomized
2 inhibitors in kidney
with mifepristone before
in Vancomycin-Treated
Treatment Regimens: A
Controlled Trial to Deter-
disease progression. iFo-
surgery. Clinical Med In-
Rats. Antimicrobial Agents
Review of What We Have
mine the Efficacy of Early
rumRx, November 2016.
sights: Endocrinology and
and Chemotherapy, 2016
and What We Need.
Switch From Vancomycin
Diabetes, 2016;9:31-6.
Sep 23;60(10):5742-51.
Infectious Diseases and
to Vancomycin Alterna-
Jacqueline Cleary
Therapy 2016 Jul 6 (ePub
tives as a Strategy to
Cleary J, Nicewicz K, Fu-
Kane MP, Hamilton RA.
Lodise TP, Bidell MR, Fla-
ahead of print).
Prevent Nephrotoxicity in
din J. Life-Saving Nalox-
Determination of the gly-
nagan SD, Zasowski EJ,
Patients With Multiple Risk
one: Review of Currently
cemic index of a diabetes
Minassian SL, Prokocimer
Lodise TP, Bidell MR,
Factors for Adverse Renal
Approved Products. Prac-
truffle. Journal of Global
P. Characterization of the
Flanagan SD, Zasowski
Outcomes (STOP-NT). An-
tical Pain Management,
Diabetes and Clinical Me-
haematological profile
EJ, Minassian SL, Proko-
nals of Pharmacotherapy,
2016 September 16(7).
tabolism, 2016;1:22-4.
of 21 days of tedizolid
cimer P. Characterization
2016 Nov 11. Atkinson TJ, Pratt Cleary
Brady SM, Kane MP,
Journal of Antimicrobial
of the haematological
in healthy subjects.
profile of 21 days of
Carreno JJ, Lomaestro
J, Fudin J. 10 Pain Medi-
Busch RS. GLP-1 Agonist
Chemotherapy, 2016
tedizolid in healthy
B, Jacobs AM, Meyers
cation Myths: Challenges
Use in a Patient with
Sep;71(9):2553-8.
subjects. Journal of Anti-
RM, Evans A, Montero
in Selecting the Appropri-
an Explainable Cause
microbial Chemotherapy
C. Assessment of Time
ate Analgesic. Practical
of Pancreatitis. AACE
Jensen IS, Wu E, Fan W,
2016 Jun 17 (ePub ahead
to Clinical Response
Pain Management, 2016
Clinical Case Reports.
Lodise TP, Nicolau DP,
of print).
in Patients with Sepsis
July/August 16(6): 63-70.
Spring, 2016. DOI 10.4158/
Dufour S, Cyr PL, Sulham
EP15658.CR.
KA. Use of Oritavancin
Treated Before and After
in Moderate-to-Severe
Bidell MR, Lodise TP.
a Implementation of a
Michael Kane
Fluoroquinolone-Associ-
Matrix-Assisted Laser De-
Stryker MD, Kane MP,
Thomas Lodise
ABSSSI Patients Requiring
ated Tendinopathy: Does
sorption Ionization Time
Busch RS. Lack of
Rahbar AJ, Lodise TP,
IV Antibiotics: A U.S. Pay-
Levofloxacin Pose the
of Flight Based Blood
Cross-Reactivity Allergy
Abraham P, Lockwood
er Budget Impact Analy-
Greatest Risk? Pharmaco-
Culture Identification Al-
Following a Switch from
A, Pai MP, Patka J, Rabi-
sis. Journal of Managed
therapy 2016 May 3
gorithm. Infection Control
Alirocumab to Evolocum-
novich M, Curzio K, Ches-
Care & Specialty Pharma-
(ePub ahead of print).
& Hospital Epidemiology,
ab. Excerpts in Pharma-
ter K, Williams B, Morse B,
cy, 2016 Jun;22(6):752-
2016 Aug;37(8):916-23.
cy Research Journal,
Chaar M, Huang V, Salo-
64. doi: 10.18553/
doi: 10.1017/ice.2016.105.
2016;2:1-3.
mone J. Pharmacokinetic
jmcp.2016.22.6.752.
Bidell MR, Palchak M,
and Pharmacodynamic
Mohr J, Lodise TP. Fluoroquinolone and Third-Gen-
Katie Cardone
Stryker MD, Kane MP,
Evaluation of Doripenem
Bidell MR, Palchak M,
eration Cephalosporin
Parker WM, Ferreira K,
Busch RS. An Evaluation
in Critically Ill Trauma
Mohr J, Lodise TP. Fluoro-
Resistance among
Vernon L, Cardone KE.
Of Proprotein Convertase
Patients with Sepsis. Sur-
quinolone and Third-Gen-
Hospitalized Patients with
The delicate balance of
Subtilisin/Kexin Type
gical Infections (Larchmt),
eration-Cephalosporin
Urinary Tract Infections
keeping it all together:
9 (PCSK9) Inhibitors In
2016 Dec;17(6):675-682.
Resistance among
Due to Escherichia
Using social capital
Patients With Diabetes
coli: Do Rates Vary by
to manage multiple
Mellitus. Journal of Clini-
Rhodes NJ, Prozialeck
Urinary Tract Infections
Hospital Characteristics
medications for patients
cal Lipidology, 10(3):720,
WC, Lodise TP, Venka-
Due to Escherichia coli:
and Geographic Region?
on dialysis. Research in
May 2016.
tesan N, O’Donnell JN,
Do Rates Vary by Hospi-
Antimicrobial Agents and
Social and Administrative
Pais G, Cluff C, Lamar PC,
tal Characteristics and
Hospitalized Patients with
S CH O LA R LY ACT IV IT Y R EP O RT AC P H S P RE SID E N T’ S RE P O RT 29
Geographic Region?
Martirosov DM, Lodise TP.
Rhodes NJ. Investigating
N. Desirable Characteris-
Sarah (Scarpace) Peters
Antimicrobial Agents and
Emerging trends in epide-
the extremes of antibiotic
tics of Hepatitis C Treat-
Ignoffo R, Knapp K,
Chemotherapy, 2016 Apr
miology and management
use with an epidemiologic
ment Regimens: A Review
Barnett M, Yowell Barbour
22;60(5):3170-3.
of infections caused by
framework. Antimicrobial
of What We Have and
S, D’Amato S, Iacovelli
carbapenem-resistant
Agents and Chemotherapy
What We Need. Infectious
L, Knudsen J, Koontz SE,
Jensen IS, Lodise TP, Fan
Enterobacteriaceae. Diag-
2016; 60: 3265-3269.
Diseases and Therapy,
Mancini R, McBride A,
W, Wu C, Cyr PL, Nicolau
nostic Microbiology and
2016 Sep;5(3):299-312.
McCauley D, Medina P,
DP, DuFour S, Sulham
Infectious Diseases, 2016
O’Donnell JN, Miglis CM,
doi: 10.1007/s40121-016-
O’Bryan CL, Scarpace
KA. Use of Oritavancin in
Jun;85(2):266-75.
Lee JY, Tuvell M, Lerthar-
0118-x. Epub 2016 Jul 6.
S, Stricker S, Trovato JA.
akul T, Scheetz MH. Car-
Review.
Board-certified oncology
Acute Bacterial Skin and
pharmacists: their poten-
Skin Structure Infec-
J. Nicholas O’Donnell
bapenem susceptibility
tions Patients Receiving
Rhodes NJ, Prozialeck
breakpoints, clinical impli-
Britt NS, Potter EM, Patel
tial contribution to reduc-
Intravenous Antibiotics:
WC, Lodise TP, Venka-
cations with the moving
N, Steed ME. Compar-
ing a shortfall in oncology
A US Hospital Budget
tesan N, O’Donnell JN,
target. Expert Review of
ative Effectiveness and
patient visits. Journal of
Impact Analysis. Clinical
Pais G, Cluff C, Lamar
Anti-infective Therapy; 14:
Safety of Standard-,
Oncology Practice 2016;
Drug Investigation, 2016
PC, Neely MN, Gulati A,
389-401.
Medium-, and High-Dose
epub22 March 2016. doi:
Feb;36(2):157-68.
Scheetz MH. Evaluation of
Daptomycin Strategies
10.1200/JOP.2015.008490.
vancomycin exposures as-
O’Donnell JN, Venkate-
for the Treatment of
Lodise TP, Fan W, Sulham
sociated with elevations in
san N, Manek M, Rhodes
Vancomycin-Resistant
Joanna Schwartz
KA. Economic Impact of
novel urinary biomarkers
NJ, Scheetz MH. Visual
Enterococcal Bactere-
Moukharskaya J, Abrams
Oritavancin for the Treat-
of acute kidney injury in
and absorbance analyses
mia Among Veterans
DM, Khan FB, Schwartz
ment of Acute Bacterial
vancomycin-treated rats.
of vancomycin and pip-
Affairs Patients. Clinical
J, Ades S, Ashikaga T.
Skin and Skin Structure In-
Antimicrobial Agents and
eracillin-tazobactam in-
Infectious Diseases 2016
Randomized Phase 2
fections in the Emergency
Chemotherapy 2016; 60:
compatibilities at a range
Dec 22. pii: ciw815. doi:
Study of Loratadine for
Department or Observa-
5742-5751.
of commonly utilized dos-
10.1093/cid/ciw815 (ePub
the prevention of bone
es. American Journal of
ahead of print).
pain cause by pegfil-
tion Setting: Cost Savings
grastim. Supportive Care
Associated with Avoidable
Whited L, Grove M, Rose
Health-System Pharmacy
Hospitalizations. Clinical
D, Rhodes NJ, Scheetz
2016; 73: 241-246.
Therapeutics, 2016 Jan
MH, O’Donnell JN, Neeb
1;38(1):136-48.
J, Thoele K, Jones DR,
Rhodes NJ, O’Donnell JN,
RT, Steed ME. Relation-
Britt NS, Patel N, Shireman
Cancer, July 2016; 24(7):
TI, El Atrouni WI, Horvat
3085-3093.
Lowe C, Moore D, Kiel
Lizza BD, Mclaughlin MM,
ship between vancomycin
Kimberly Skylstad
Moise PA, Culshaw DL,
PJ. Pharmacokinetics
Esterly JS, Scheetz MH.
tolerance and clinical
Garren T, Skylstad
Wong-Beringer A, Bens-
of cefepime in patients
Tree based models for the
outcomes in Staphylococ-
KA. Scaffolded Online
man J, Lamp KC, Smith
with cancer and febrile
prediction of mortality in
cus aureus bacteraemia.
Learning Modules for
WJ, Bauer K, Goff DA,
neutropenia in the setting
Gram negative bacte-
Journal of Antimicrobial
Milliequivalency and
Adamson R, Leuthner K,
of hematologic malig-
remia: avoid putting the
Chemotherapy 2016
Milliosmolarity. Currents
Virata MD, McKinnell JA,
nancies or hematopoi-
CART before the horse.
Dec 20. pii: dkw453. doi:
in Pharmacy Teaching and
Chaudhry SB, Eskandar-
etic cell transplantation.
Antimicrobial Agents and
10.1093/jac/dkw453 (ePub
Learning 2016;8:316-322.
ian R, Lodise T, Reyes K,
Pharmacotherapy 2016;
Chemotherapy 2016; 60:
ahead of print).
Zervos MJ. Comparative
36: 1003-1010.
838-844.
Effectiveness of Vanco-
Aimee Strang Britt NS, Patel N, Horvat
Baia P, Strang AF. Phar-
mycin Versus Daptomycin
O’Donnell JN, O’Donnell
O’Donnell JN, Gulati A,
RT, Steed ME. Vancomy-
macy Educator Motives
for MRSA Bacteremia With
EP, Gulati A, Lavhale
Lavhale MS, Sharma SS,
cin 24-Hour Area under
to Pursue Pedagogical
Vancomycin MIC >1 mg/L:
MS, Kumar EJ, Scheetz
Patel AJ, Rhodes NJ,
the Curve/Minimum Bac-
Knowledge. American
A Multicenter Evaluation.
MH. Centhaquin citrate
Scheetz MH. Pharmaco-
tericidal Concentration
Journal of Pharmaceutical
Clinical Therapeutics, 2016
pharmacokinetics in a
kinetics of centhaquin
Ratio as a Novel Predictor
Education, 2016; 80(8): 132.
Jan 1;38(1):16-30.
dog model. Journal of
citrate in a rat model.
of Mortality in Methicil-
Strang AF, Baia P. An
Pharmacy and Pharmacol-
Journal of Pharmacy and
lin-Resistant Staphylococ-
Investigation of Teaching
ogy 2016; 68: 803-809.
Pharmacology 2016; 68:
cus aureus Bacteremia.
and Learning Programs
56-62.
Antimicrobial Agents and
in Pharmacy Education.
Chemotherapy 2016 Apr
American Journal of
Bidell MR, Lodise TP. Fluoroquinolone-Associated Tendinopathy: Does Levo-
Scheetz MH, Crew PE,
floxacin Pose the Greatest
Miglis C, Gilbert EM,
Nimish Patel
22;60(5):3070-5. doi:
Pharmaceutical Education,
Risk? Pharmacotherapy,
Sutton SH, O’Donnell JN,
Bidell MR, McLaughlin M,
10.1128/AAC.02714-15,
2016; 80(4):59.
2016 Jun;36(6):679-93.
Postelnick M, Zembower T,
Faragon J, Morse C, Patel
May 2016.
30 AC P H S
PR ESI DENT’ S R EPORT SC HOLARLY AC TIV ITY REPORT
Lamba S, Strang A,
Cardone KE. “End-Stage
Care Pharmacy Preparato-
Bidell MR, Lodise TP.
Parker WM, Wegrzyn NM,
Edelman D, Navedo D,
Kidney Disease” in Phar-
ry Review and Recertifi-
Levofloxacin-associated
Pai AB, Daoui R, Daoui
Soto-Greene ML, Guarino
macotherapy Casebook:
cation Course, 2016 ed.
tendinopathy: What is the
S, Cardone KE. Health
AJ. Promoting inter-
A Patient-Focused Ap-
Bainbridge JL, Cardone
risk? ACPHS Research Fo-
Literacy and Self-Man-
professionalism: initial
proach, 10th ed. Schwing-
K, Cross LB, et al. Lenexa,
rum, Albany, NY, January
agement of Medications
evaluation of a master of
hammer TL, Koehler JM,
KS: American College of
2016; Making A Difference
among Patients at an
science in health profes-
eds., McGraw-Hill, 2016.
Clinical Pharmacy, 2016:1-
in Infectious Diseases
Outpatient Nephrology
679 - 1-740.
(MAD-ID), Orlando, FL,
Office. AcademyHealth
May 2016.
Annual Research Meet-
sions education degree program. Advances in
Cardone KE. “Nephrol-
Medical Education and
ogy” in Review and
Sarah (Scarpace) Peters
Practice, 2016; 7: 51–5.
Recertification Book for
Adams VR, Peters
Laurie Briceland
Board Certification in Am-
SS. “Lung Cancer” in
Rosa S, Briceland L. Intro-
Matthew Stryker
bulatory Care Pharmacy.
Pharmacotherapy:
ducing students to Phar-
Wegrzyn NM, Parker
Stryker M, Kane M, Busch
American College of Clini-
A Pathophysiologic
macy Ownership through
WM, Pai AB, Daoui R,
R. Lack of Cross-Reactivi-
cal Pharmacy, 2016.
Approach, 10th ed. DiPiro
the development of an
Daoui S, Cardone KE.
JT, Talbert RL, Yee GC,
Entrepreneurial APPE Ro-
Assessing health literacy
ty Following a Switch from
ing, Boston, MA, June 27, 2016.
Alirocumab to Evolocum-
Jacqueline Cleary
Matzke GR, Wells BG,
tation. 2016 AACP Annual
in outpatient nephrology
ab. Excerpts in Phar-
Fudin J, Pratt Cleary J,
Posey LM., eds. New York,
Meeting (abstract).
patients. National Kidney
macy Research Journal
Sparkes S. “Opioid Anal-
NY: McGraw-Hill Educa-
2016;2:1-2.
gesics” in Pain Manage-
tion, 2016.
ment Secrets, Fourth ED. Stryker M, Kane M, Busch
Dubin, Andrew, et al,
R. A Pharmacist-Run
Elsevier Health Scienc-
Proprotein Convertase
es, 2016 (publication
Subtilisin/Kexin Type 9
pending).
(PCSK9) Inhibitor Clinic:
PRESENTATIONS
Foundation Spring CliniBriceland L, Rosa S,
cal Meeting, Boston, MA,
Lubowski T, Jablanski C.
April 2016.
Creation of Experiential Education Honors Policies
Brian Cowles
to Recognize Exemplary
Lipinksi H, Cowles B,
IPPE and APPE Perfor-
Young L. Dobutamine-in-
Monique Bidell
mance. AACP Annual
duced rash in a critically
P O ST E R /PLATFOR M P RESE NTATIONS
Short-Tem Results and
Jessica Farrell
Fimansyah A, Nguyen H,
Meeting, Anaheim, CA,
ill full-term neonate:
Practical Strategies. Phar-
Farrell JF, Kennedy
Bidell M, Han Z, Pettit NN.
July 25, 2016 (abstract).
A case report. ASHP
macotherapy 2016;36(7)
AG. “Psoriatic Arthritis”
Outcomes associated with
e83-e138.
in Ambulatory Care
time-to-antibiotic admin-
Katie Cardone
Las Vegas, NV, December
Self-Assessment Program
istration among patients
Cardone KE, Daoui S,
6, 2016.
Stryker M, Kane M, Busch
(ACSAP), 2016 Book 1,
with febrile neutropenia
Daoui R, Donato KM,
R. An Evaluation of Pro-
Endocrinologic/Rheuma-
in the emergency de-
Parker WM. Factors
Jessica Farrell
protein Convertase Subtil-
tologic Care. Dong BJ,
partment. ASHP Midyear
Affecting Medication
Farrell JF. Pharmacist-
isin/Kexin Type 9 (PCSK9)
Elliott DP, eds. Lenexa,
Exhibition, Las Vegas, NV,
Management among
Developed Letters
Inhibitors in Patients with
KS: American College
December 2016.
Patients with Chronic
Used to Obtained
Diabetes Mellitus. Journal
of Clinical Pharmacy,
Kidney Disease (abstract
Inclusion of Off-Label
of Clinical Lipidology,
2016.
Brown SJ, Lane SM, Bidell
SA-PO924). American So-
Indications of Rheumatic
MR. Assessment of insti-
ciety of Nephrology 2016
Drugs within National
Michael Kane
tutional fluoroquinolone
Kidney Week, Chicago, IL,
Compendia. Scleroderma
Jonklaas J, Kane MP.
use for uncomplicated
November 2016. Journal
Foundation National Pa-
“Thyroid disorders”
infections. ASHP Midyear
of the American Society of
tient Education Confer-
Katie Cardone
in Pharmacotherapy:
Exhibition, Las Vegas, NV,
Nephrology 27:2016.
ence, New Orleans, LA,
Wegrzyn NM, Cardone
A Pathophysiologic
December 2016.
KE. “Are intravenous
Approach, 10th edition.
iron sucrose products
DiPiro JT, Talbert RL, Yee
Falli E, Poucher A, Lom-
Balk N, Rivenburg K,
Loy T, Farrell JF, Bruce
interchangeable? Efficacy
GC, Matzke GR, Wells
bardi CL, Ferri D, Bidell
DiCenzo R. Promoting
SP. Pharmacist- and
and safety of original and
BG, Posey LM, eds. New
MR. Evaluation of an
Pharmacy through
student-developed letters
generic formulations in
York, NY: McGraw-Hill
adjusted body weight-
Recruitment for Two
to national compendia to
hemodialysis patients.”
Education, 2016.
based vancomycin dosing
Campuses in Two States.
acquire off-label status.
guideline. ASHP Midyear
American Association of
ASHP Midyear Clinical
10(3):720, May 2016.
BOOK CHAPTERS
Textbook Update, Ac-
Midyear Clinical Meeting,
July 2016. Cardone KE, Zheng H,
cessPharmacy Web site,
Kane MP. “Endocrine
Exhibition, Las Vegas, NV,
Colleges of Pharmacy An-
Meeting & Exhibition, Las
New York: McGraw-Hill,
Disorders” in Updates in
December 2016.
nual Meeting, Anaheim,
Vegas, NV, December
September 2016.
Therapeutics: Ambulatory
CA, July 23-27, 2016.
2016.
S CHO LA R LY ACT IV IT Y R EP O RT AC P H S P RE SID E N T’ S RE P O RT 31
Gina Garrison
Rafie S, Shealy K, Stone
M, Berger A. Clinical
Huang D, Lodise T. Use of
tients (abstract SAT-223).
Quidort A, Wales D,
R, Vernon V. The Women’s
and Economic Burden
PK/PD Systems Analyses
Poster presentation at
Garrison GD, Lindstrom J,
Health PRN Members and
of Multi-drug Resistant
to Determine the Optimal
the European Associa-
Verrico I. Improving Immu-
Accomplishments. Amer-
Pseudomonas sp. (MDRP)
Fixed Dosing Regimen of
tion for the Study of the
nization Rates of Children
ican College of Clinical
Among Patients with
Iclaprim (ICL) for Phase III
Liver – International Liver
Age 19 to 35 months:
Pharmacy (ACCP) Annual
Serious Infections in US
ABSSSI Clinical Trial. Ab-
Congress, Barcelona, ES,
An Interprofessional
Meeting, Hollywood, FL,
Hospitals (abstract 2045).
stract 1971. Poster Presen-
April 2016.
Approach at a Multidis-
October 2016.
Poster Presentation at ID-
tation at IDWeek2016™:
Presenter: Patel.
Week2016, New Orleans,
A Joint Meeting of IDSA,
ciplinary Training Site. American Academy of
Thomas Lodise
LA, October 26-30, 2016.
SHEA, HIVMA, and PIDS.
Yager J, Lodise T, Patel
Pediatrics (AAP) National
Lodise TP, Ye M, Keyloun
Presenter: Lodise.
New Orleans, LA, October
N. Minimum adherence
Conference & Exhibition,
KR, Zhao Q, Gillard P.
26-30, 2016.
threshold necessary to
San Francisco, CA,
Identification of Patients
Mckinnell JA, Corman
Presenter: Huang.
achieve virologic sup-
October 22-25, 2016.
at Greatest Risk for
S, Patel D, Lodise TP.
Carbapenem Resistance
Telavancin vs. Vanco-
Carreno JJ, Lomaestro
Poster presentation at the
Michael Kane
in Patients With Serious
mycin in the Treatment
BM, Tietjan J, Lodise T.
26th European Congress
Stryker M, Kane M, Busch
Hospital-Onset Infections
of Hospital-Acquired
Validation Of A Bayesian
on Clinical Microbiology
R, Hamilton R. An Evalu-
Due to Enterobacteria-
Pneumonia Caused by S.
Approach To Estimate
and Infectious Diseases,
ation of Proprotein Con-
ceae Species (abstract
Aureus: Decision Analytic
Vancomycin Exposure
Amsterdam, NL, April
vertase Subtilisin/Kexin
1794). Oral Presentation
Model (abstract 1250).
In Obese Patients With
2016. Presenter: Patel.
Type 9 (PCSK9) Inhibitors
at IDWeek2016, New Or-
Poster Presentation at ID-
Limited PK Sampling
in Patients with Diabetes
leans, LA, October 26-30,
Week2016, New Orleans,
(abstract 496). Poster
Patel N, Yager J, McGuey
Mellitus (abstract 187).
2016. Presenter: Lodise.
LA, October 26-30, 2016.
Presentation at ASM
L, Hoye-Simek A, Lodise
Presenter: Mckinnell JA.
Microbe 2016, Boston,
T. Relationship between
MA, June 16-20, 2016.
single-tablet regimen
Presenter: Carreno.
and adherence to HIV
National Lipid Associa-
pression (abstract 1995).
tion’s Scientific Sessions,
Berger A, Bhagnani T,
New Orleans, LA,
Wang R, Zhao Q, Ye M,
Martin A, Fahrbach K,
May 18, 2016.
Lodise TP. Does Timing
Zhao Q, Lodise T. Associ-
of Receipt of Appropriate
ation between Carbap-
O’Donnell J, Rhodes NJ,
(abstract 1998). Poster
Stryker M, Kane M, Busch
Antimicrobial Thera-
enem Resistance and
Lodise T, Prozialeck W,
presentation at the 26th
R, Hamilton R. A Pharma-
py Make a Difference
Mortality among Adults
Miglis CH, Natarajan V,
European Congress on
cist-Run Proprotein Con-
Among Patients with
Hospitalized with Serious
Joshi M, Pais G, Lamar P,
Clinical Microbiology and
vertase Subtilisin/Kexin
Serious Infections due to
Infections due to an
Cluff C, Gulati A, Scheetz
Infectious Diseases, Am-
Type 9 (PCSK9) Inhibitor
Resistant Gram-negative
Enterobacteriaceae spp:
MH. 24-Hour Pharmaco-
sterdam, NL, April 2016.
Clinic: Short-Term Results
Pathogens? (abstract
Results of a Systematic
kinetic Relationships for
Presenter: Patel.
and Practical Strategies
1796). Oral Presentation
Literature Review and
Vancomycin (Van) and
(poster 97). American
at IDWeek2016, New Or-
Meta-Analysis (abstract
Novel Urinary Biomarkers
Patel N, Hecox Z, Morse
College of Clinical
leans, LA, October 26-30,
355). Poster Presentation
of Acute Kidney Injury
C, Sullivan S, Hoye-Simek
Pharmacy’s Virtual Poster
2016. Presenter: Lodise.
at IDWeek2016, New Or-
(abstract 517). Poster Pre-
A, Yager J, Lodise T.
leans, LA, October 26-30,
sentation at ASM Microbe
Maintenance of non-HIV
2016. Presenter: Martin.
2016, Boston, MA, June
cardiometabolic comor-
16-20, 2016. Presenter:
bidity control among
O’Donnell.
HIV-infected veterans’
Symposium, May 18, 2016. Luther M, Caffrey A, Dosa
and non-HIV medications
Bizier J, Kane MP, Busch
D, Lodise TP, LaPlante
RS, Bakst G, ElDeiry SE,
K. Vancomycin plus
Natesan S, Pai MP, Lodise
Hamilton RA. Efficacy
Piperacillin/Tazobactam
TP. Determination of
and Safety of Switch-
and Acute Kidney Injury
Alternative Ceftolozane/
Schriever C, Ahmed A,
comparison between
ing Sodium-Glucose
in Adults: A Systematic
Tazobactam (C/T) Dosing
Delehanty KR, Yager J,
single tablet and multiple
Cotransporter-2 (SGLT-2)
Review and Meta-anal-
Regimens for Patients
Farrow G, Kashtan R,
tablet antiretroviral
Inhibitor Therapy in Type
ysis (abstract 1805).
with Infections Due to
Lodise T, Patel N. Com-
regimens (abstract 1991).
2 Diabetes Mellitus. ASHP
Poster Presentation at ID-
Pseudomonas aerugi-
parison of frequencies of
Poster presentation at
Midyear Clinical Meeting,
Week2016, New Orleans,
nosa with high (C/T) MIC
drug-drug interactions
the 26th European
Las Vegas, NV,
LA, October 26-30, 2016.
values (abstract 1959).
between sofosbuvir/le-
Congress on Clinical
December 7, 2016.
Presenter: Luther.
Poster Presentation at ID-
dipasvir and ombitasvir/
Microbiology and
Week2016, New Orleans,
dasabuvir/paritaprevir/ri-
Infectious Diseases, Am-
affairs patients: a
Nicole Lodise
Lodise TP. Wang R,
LA, October 26-30, 2016.
tonavir +/- ribavirin among
sterdam, NL, April 2016.
Bartelme KM, Lodise NM,
Bhagnani T, Zhao Q, Ye
Presenter: Natesan.
HIV/HCV coinfected pa-
Presenter: Patel.
32 ACP H S
PR ESI DENT’ S R EPORT SC HOLA RLY AC TIV ITY REPORT
to Recognize Exemplary
Yager J, Lodise T, Patel
cardiometabolic comor-
pean Association for the
Treatment of Hepatitis C
N. Minimum adherence
bidity control among
Study of the Liver – Inter-
Monoinfection (abstract
IPPE and APPE Perfor-
threshold needed for
HIV-infected veterans’
national Liver Congress,
60260). Poster presenta-
mance. AACP Annual
maintenance of virologic
affairs patients: a com-
Barcelona, ES, April 2016.
tion at IDWeek 2016. New
Meeting, Anaheim, CA,
suppression (abstract
parison between single
Presenter: Patel.
Orleans, LA, October 2016.
July 25, 2016 (abstract).
1993). Platform presenta-
tablet and multiple tablet
tion at the 26th European
antiretroviral regimens
Britt NS, Potter EM, Patel
Congress on Clinical Mi-
(abstract 1991). Poster
N, Steed ME. Derivation
Yager J, Faragon J, Patel
Stryker M, Kane M, Busch
crobiology and Infectious
presentation at the 26th
And Validation Of A
N. Quantifying the mini-
R, Hamilton R. An Evalu-
Diseases, Amsterdam, NL,
European Congress on
Mortality Risk Assessment
mum adherence threshold
ation of Proprotein Con-
April 2016.
Clinical Microbiology and
Model For Vancomy-
associated with the
vertase Subtilisin/Kexin
Presenter: Yager.
Infectious Diseases, Am-
cin-Resistant Entero-
development of reverse
Type 9 (PCSK9) Inhibitors
sterdam, NL, April 2016.
coccal (Vre) Bacteremia
transcriptase mutations
in Patients with Diabetes
Presenter: Patel.
Based On Source Of
among HIV-infected
Mellitus. 2016 National
Infection (session 333).
Veterans’ Affairs patients
Lipid Association’s Sci-
O’Donnell JN, Rhodes NJ, Lodise TP, Prozialeck
Presenter: Patel. Matthew Stryker
WC, Miglis CM, Venka-
Patel N, Yager J, McGuey
Platform presentation
receiving antiretroviral
entific Sessions, Abstract
tesan N, Joshi M, Pais G,
L, Hoye-Simek A, Lodise
at American Society for
therapy (abstract 225954).
Identification: 187.
Lamar PC, Cluff C, Gulati
T. Relationship between
Microbiology Microbe
Poster Presentation at
A, Scheetz MH. 24-hour
single-tablet regimen
Meeting, Boston, MA,
the 2016 ASHP Midyear
Stryker M, Kane M, Busch
pharmacokinetic relation-
and adherence to HIV
June 2016.
Clinical Meeting, Las Ve-
R, Hamilton R. A Pharma-
ships for vancomycin and
and non-HIV medications
Presenter: Britt.
gas, NV, December 2016.
cist-Run Proprotein Con-
novel urinary biomarkers
(abstract 1998). Poster
Presenter: Yager.
vertase Subtilisin/Kexin
of AKI. 1st American
presentation at the 26th
Britt NS, Potter EM, Patel
Society of Microbiology
European Congress on
N, Steed ME. Clinical Out-
Sangiovanni RJ, Yager
Clinic: Short-Term Results
Microbe, Boston, MA,
Clinical Microbiology and
comes In Vancomycin-Re-
J, Donadio A, Farrow G,
and Practical Strategies.
June 2016.
Infectious Diseases, Am-
sistant Enterococcus
Patel N. Use of vancomy-
American College of
sterdam, NL, April 2016.
(VRE)/Methicillin-Resistant
cin in VISN-2 patients who
Clinical Pharmacy’s 2016
Presenter: Patel.
Staphylococcus aureus
have previously experi-
Virtual Poster Sympo-
(MRSA) Bloodstream
enced vancomycin-asso-
sium, Poster Number: 97.
Lee Anna Obos Obos L. Two Phase Phar-
Type 9 (PCSK9) Inhibitor
macy Skills Laboratory
Yager J, Lodise T, Patel
Coinfection Treated With
ciated acute kidney injury
Video Project: Student
N. Minimum adherence
Daptomycin Or Linezolid
(AKI): Predictors and
Reactions and Effect on
threshold necessary to
(abstract 396). Poster
outcomes of secondary
INVITED PR ESENTATIONS
Lab Performance, AACP
achieve virologic sup-
presentation at American
vancomycin-associated
Kelly Bach
Annual Meeting, Ana-
pression (abstract 1995).
Society for Microbiology
AKI (abstract 225960).
Bach K. Delivering a pow-
heim, CA, July 2016.
Poster presentation at the
Microbe Meeting, Boston,
Poster presentation at
erful residency interview
26th European Congress
MA, June 2016.
the 51st ASHP Midyear
presentation. ACPHS/
Nimish Patel
on Clinical Microbiology
Presenter: Britt.
Clinical Meeting and
NYSCHP Residency
Yager J, Lodise T, Patel
and Infectious Diseases,
Exhibition, Las Vegas, NV,
Preparation Symposium,
N. Minimum adherence
Amsterdam, NL, April 2016.
Ahmed AA, Schriever C,
December 2016.
ACPHS, Albany, NY,
threshold needed for
Presenter: Patel.
Amin R, Delehanty KR,
Presenter: Sangiovanni.
October 2016.
Yager J, Patel N. Compar-
maintenance of virologic suppression (abstract
Schriever C, Ahmed A,
ing the Population-Based
Sandra Rosa
Monique Bidell
1993). Platform presenta-
Delehanty KR, Yager J,
Frequency of Contraindi-
Rosa S, Briceland L.
Bidell M. A case of
tion at the 26th European
Farrow G, Kashtan R, Lo-
cated Drug-Drug Interac-
Introducing students to
vomiting, malaise and
Congress on Clinical Mi-
dise T, Patel N. Compari-
tions between Daclatasvir/
Pharmacy Ownership
acute injury (co-presented
crobiology and Infectious
son of frequencies of drug-
Sofosbuvir (DAC/SOF),
through the development
with Yolana Fuks and
Diseases, Amsterdam, NL,
drug interactions between
Grazoprevir/Elbasvir (GZR/
of an Entrepreneurial
David Colman). Medical
April 2016.
sofosbuvir/ledipasvir and
EBV), Ledipasvir/Sofosbu-
APPE Rotation. 2016 AACP
Grand Rounds, St. Peter’s
Presenter: Yager.
ombitasvir/dasabuvir/
vir (LDV/SOF), Ombitasvir/
Annual Meeting (abstract).
Hospital, Albany, NY,
paritaprevir/ritonavir
Paritaprevir/Ritonavir +
Patel N, Hecox Z, Morse
+/- ribavirin among HIV/
Dasabuvir ± Ribavirin
Briceland L, Rosa S,
C, Sullivan S, Hoye-Simek
HCV coinfected patients
(OMB/PTV/RTV + DSV
Lubowski T, Jablanski C.
Bidell M. Fluoroquino-
A, Yager J, Lodise T.
(abstract SAT-223). Poster
± RBV) and Simeprevir/
Creation of Experiential
lone safety: Tipping
Maintenance of non-HIV
presentation at the Euro-
Sofosbuvir (SIM/SOF) for
Education Honors Policies
the risk-benefit scale.
December 2016.
S CH O LA R LY ACT IV IT Y R EP O RT AC P H S P RE SID E N T’ S RE P O RT 33
PharmaMed 2016, Dubai,
Continuing Education.
Utica, NY, December 2016.
Cardone K. Update on
Jo Carreno
United Arab Emirates,
November 2016.
Cardone K. Use of SGLT2
Diabetic Kidney Disease
Carreno J. Zika Virus:
Inhibitors in Treating T2D.
(DKD) Management:
Beyond the Hype. Con-
Brodeur MR. Falls and
Continuing Education. Mo-
SGLT-2 inhibitors. Continu-
tinuing Education. Capital
Bidell M. Why complete
Their Prevention: A
hawk Valley Pharmacists
ing Education. National
Area Pharmacists Society,
a pharmacy residency
Geriatrics and Pharma-
Association, Utica, NY,
Kidney Foundation Spring
Albany, NY.
and how to prepare to be
cological Imperative Fall
December 2016.
Clinical Meeting, Boston
a competitive candidate
Risk Identification and
(co-presented with Kate
Intervention for the Com-
Cardone K. Updates In
Cabral). ACPHS/NYSCHP
munity-Dwelling Older
Type 2 Diabetes Man-
Cardone K. Anemia Work-
Residency Preparation
Adult. Public Health Live,
agement: Case-Based
shop: Management of ESA
Programs. Continuing Edu-
Symposium, ACPHS, Al-
SUNY School of Public
Discussion Of Diabetes
Hyporesponse: A Fine
cation. ACPHS, Albany, NY.
bany, NY, October 2016.
Health, October 20, 2016.
Management. Continuing
Balance. Continuing Ed-
Education (co-presented
ucation. National Kidney
Jacqueline Cleary
December 2016.
MA, May 2016.
Carreno J. The Use of Rapid Diagnostics within Antimicrobial Stewardship
Bidell M. Updates in an-
Brodeur MR. Pill Pruning
with See-Won Seo). Mo-
Foundation Spring Clinical
Cleary J. Opioid Induced
timicrobial safety: Focus
- The Art and Science of
hawk Valley Pharmacists
Meeting, Boston, MA,
Respiratory Depression
on fluoroquinolones.
Deprescribing. Office of
Association, Utica, NY,
May 2016.
and In-Home Naloxone
Continuing Education.
Postgraduate Education,
December 2016.
Infectious Diseases Sym-
ACPHS, June 8, 2016.
Use: Application of the Cardone K. Pragmatic
Risk Index for Overdose
Cardone K. Pharmacolo-
Drug Dosing across the
or Serious Opioid Induced
Brodeur MR. Pain Man-
gy, Pharmacokinetics and
Continuum in Kidney Dis-
Respiratory Depression
agement in an Era of Un-
Pharmacodynamics in
ease: Drug Dosing In He-
(RIOSORD) Tool. Con-
Abby Boire
certainty. Pharmacist So-
Diabetic Kidney Disease:
modialysis – Time Over
tinuing Education. Alden
Boire A. Updates in Heart
ciety of the State of New
Give It Your Best Shot:
Matter? Continuing Edu-
March Bioethics Institute
Failure Therapy: What
York (PSSNY), Mid-Winter
Newer Diabetes Agents
cation and Active Learning
Clinical Ethics Confer-
the Pharmacist Needs to
Meeting, Saratoga, NY,
in CKD. Continuing Educa-
Case Session. National
ence, ACPHS, Albany, NY,
Know. April 2016.
January 30, 2016.
tion. American Society of
Kidney Foundation Spring
November 19, 2016.
Nephrology Kidney Week,
Clinical Meeting, Boston,
posium, ACPHS, Albany, NY, February 2016.
Jeffrey Brewer
Katherine Cabral
Chicago, IL, November
MA, May 2016 (session
Cleary J. Pharmacist’s
Brewer JM. Professional
Why Complete a Pharma-
2016.
chair/moderator).
Role in Naloxone Educa-
Organizations Council:
cy Residency? NYSCHP/
AACP Interim Meeting Re-
ACPHS Residency Prep
Cardone K. Newer Agents
Cardone K. Pragmatic
Chi and PLS joint meeting,
port, Effective Leadership,
Symposium, Albany
and Their Implications for
Drug Dosing across the
ACPHS, Albany, NY,
Spring 2016.
College of Pharmacy and
Patients with Chronic Kid-
Continuum In Kidney
November 2016.
Health Sciences, Albany
ney Disease: The Current
Disease: Drug Dosing
NY, October 2016.
and Potential Role of
In Peritoneal Dialysis.
Cleary J. Opioid Induced
SGLT-2 Inhibitors in
Continuing Education
Respiratory Depression
Laurie Briceland Briceland L. Overview of
tion and Distribution. Rho
Antimicrobial Therapy.
Through Thick & Thin: An
Patients with Chronic
and Active Learning Case
and Naloxone Distribu-
Sage College Nurse
Update on Anticoagu-
Kidney Disease. Continu-
Session. National Kidney
tion: Application of the
Practitioner Program,
lants. Continuing Educa-
ing Education. Annual
Foundation Spring Clinical
RIOSORD Tool. Continu-
February 2016.
tion. ACPHS Cardiovas-
Meeting of the Ameri-
Meeting, Boston, MA,
ing Education. Annual
cular Symposium, Albany
can College of Clinical
May 2016 (session chair/
Preceptor Training Day,
Michael Brodeur
College of Pharmacy and
Pharmacy, Hollywood, FL,
moderator).
ACPHS, Albany, NY,
Brodeur MR. FOAM – Free
Health Sciences, Albany,
October 25, 2016.
Open Access Medical ed-
NY, April 2016.
August 2016. Cardone K. Nephrology
Cardone K. Delivering
Review for the Ambu-
Giselle D’Epiro
tion for anyone, anywhere,
Katie Cardone
Medication Therapy
latory Care Pharmacist
D’Epiro G. Vitamin
anytime. American Society
Cardone K. Updates In
Management in the
Review and recertification
Supplementation in
of Consultant Pharmacist
Type 2 Diabetes Manage-
Community. Continuing
course for board certified
Women. University of
Annual Meeting, Dallas,
ment: Guideline Updates.
Education and Certificate
ambulatory care pharma-
Vermont Women’s Health
TX, November 4, 2016.
Continuing Education
Training Program. Mo-
cists (BCACP). American
Conference, 2016.
(co-presented with See-
hawk Valley Pharmacists
College of Clinical Phar-
Brodeur MR. Colonie Emer-
Won Seo). Mohawk Valley
Association, Utica, NY,
macy Spring Conference,
gency Medical Services.
Pharmacists Association,
Spring 2016.
Phoenix, AZ, April 2016.
ucation – Medical educa-
34 ACP H S
PR ESI DENT’ S R EPORT SC HOLA RLY AC TIV ITY REPORT
D’Epiro G. The New Anti-
Presented to high school
Instructional Design Sym-
ment of new antibacterial
Difference (MAD) - ID An-
coagulants. UVM Family
students at TRIO event,
posium, Spring 2016.
therapeutics.” Superbugs
nual Meeting, Champions
Medicine Review Course,
Colchester, VT,
& Superdrugs USA 2016,
Gate, FL, May 6, 2016.
2016.
February 2016.
Jessica Farrell
Michael Kane
ship Hollywood Version
Farrell JF. Proton Pump
Kane M. Diabetes Update.
Instructional Design Sym-
The Drug: Update on
Relationships in Patients
Inhibitors (PPI): How to
American Society of Con-
posium. ACPHS, March
Treatment Options
with Infections: A Focus
Digest the News? Sclero-
sulting Pharmacists Mid-
23, 2016.
(satellite symposium).
on Beta-Lactams and
derma Foundation Na-
State New York Chapter
“The Bug-Drug-Host Triad
Vancomycin. Midwest-
tional Patient Education
Meeting and Education
Kile D. Medication Ad-
in the Era of Antibiotic
ern University, Downers
Conference, New Orleans,
Day, Syracuse, NY,
herence: America’s Other
Resistance: Focus on the
Grove, IL, April 15, 2016.
LA, July 29, 2016.
June 16, 2016.
Drug Problem. ACPHS
Spectrum of ABSSSI.” ID-
Pharmacy Practice Up-
Week2016, New Orleans,
Advanced Pharmacoki-
Farrell JF. The Role of
Kane M. Keynote Address.
date, June 8, 2016.
LA, October 28, 2016.
netics/Pharmacodynam-
Biologics in Psoriatic
The Capital District Resi-
Arthritis. Continuing Ed-
dency & Fellowship Grad-
Nicole Lodise
Economics of Treating
New York State Council of
ucation. ACPHS, Albany,
uation Luncheon, Albany,
Lodise NM. JCPP Phar-
ABSSSI in Different
Health-system Antimicro-
NY, September 2016.
NY, June 8, 2016.
macist’s Patient Care
Settings of Care (satellite
bial Stewardship Program,
Process: Standardizing
symposium). IDWeek2016,
Hosted by Greater New
David Kile
Iselin, NJ, November 16,
Kile D. Profiles in Leader-
2016.
Quantifying Antibiotic Exposure-Effect
ics (continuing education).
Gina Garrison
Kane M. Strategies for
the Approach to Patient
New Orleans, LA, October
York Hospital Association,
Garrison G. 2016 Annual
Diabetes Prevention.
Care. Continuing Educa-
27, 2016.
New York, NY, March 16,
CDC Immunization
Mid-Hudson Regional
tion. Albany College of
Updates for Adult and
Hospital Pre-diabetes
Pharmacy and Health
PK/PD versus frequentist
Infants / Children / Ado-
Epidemic Conference:
Sciences Barbara M.
approaches for drug de-
Combination Therapy for
lescents. AMC Internal
Public Health Impact
DiLascia Women’s and
velopment – Pro (debate).
Serious Gram-Negative
Medicine and Pediatrics
& Prevention of Type 2
Men’s Health Symposium,
ESCMID/ASM Conference
Infections (continuing ed-
Group, Latham, NY.
Diabetes, Poughkeepsie,
Albany, NY, September
on Drug Development to
ucation). New York State
NY, May 14, 2016.
2016.
Meet the Challenge of
Council of Health-system
Antimicrobial Resistance.
Antimicrobial Steward-
Garrison G. 2016 Updates
2016.
in Pharmacotherapy
Kane M. Endocrine Dis-
Lodise NM. Curricular
Vienna, Austria, Septem-
ship Program, Hosted by
for Adult Dyslipidemia.
orders. For Ambulatory
Adoption and Integration
ber 23, 2016.
Greater New York Hospi-
Continuing Education.
Care Pharmacy Prepa-
of the Pharmacists’ Patient
Albany Medical College
ratory Review Course,
Care Process. American
Polymyxins, What Do We
– Internal Medicine and
ACCP 2016 Updates In
Association of Colleges of
Really Know? Allergan
Pediatric Update,
Therapeutics, Phoenix,
Pharmacy (AACP) Teach-
Medical Affairs, Jersey
Nimish Patel
Saratoga, NY.
AZ, April 9, 2016.
ers’ Seminar, Anaheim,
City, NJ, June 30, 2016.
Patel N. Medication Errors
tal Association, New York, NY, March 16, 2016.
in HIV. Continuing Educa-
CA, July 2016. Lipoglycopeptides and
tion. Onondaga Pharma-
Thomas Lodise
Glycopeptides (sympo-
cists Society, Syracuse,
tions: A Synopsis. Grand
Vancomycin PK/PD Effica-
sium). “Antimicrobial
NY, June 2016.
tinuing Education. ACPHS
Rounds at the Baystate
cy (symposium). “Contem-
Toxicodynamics (Orga-
Cardiovascular Update,
Medical Center, Spring-
porary Considerations:
nized in Cooperation
Patel N. Medication Errors
Albany, NY.
field, MA, March 22, 2016.
Cutting Edge Advances
with the International
in HIV. Continuing Educa-
in Vancomycin Therapy.”
Society of Anti-Infective
tion. Capital Area Phar-
Garrison G. 2016 Updates
Kane M. The New Classes
in Pharmacotherapy for
of Diabetes Medica-
Adult Dyslipidemia. Con-
Garrison G. Dyslipidemia:
Kane M. Obesity Is a
2016 ASHP Midyear Clin-
Pharmacology (ISAP).”
macists Society, Albany,
Would every woman
Chronic Disease: Let’s
ical Meeting Las Vegas,
ASM Microbes 2016,
NY, September 2016.
should know. Capital
Treat it That Way. APhA
NV, December 7, 2016.
Boston, MA, June 20,
Region Women’s Business
Annual Meeting, Balti-
Council, Albany, NY.
more, MD, March 7, 2016.
2016.
Patel N. Updates in Epidemiology and Treatment
Exposure-Centric vs. Dose-Centric Drug Devel-
Economics of Treat-
of Sexually Transmitted
Elizabeth Higdon
Teresa Kane
opment Approach (work-
ing ABSSI in Different
Infections. Continuing Ed-
Higdon E. Calamine
Kane T. Aseptic Technique
shop). “Opportunities and
Settings of Care (satellite
ucation. ACPHS, Albany,
Compounding Workshop.
Training Videos. ACPHS
challenges in develop-
symposium). Making a
NY, September 2016.
S CHO LA R LY ACT IV IT Y R EP O RT AC P H S P RE SID E N T’ S RE P O RT 35
Patel N. Medication Errors
2016, Bretton Woods, NH.
in HIV. Continuing Educa-
Watson A. CapitalCare
Jacqueline Cleary
tion of the Pharmacists’
Medical Group Diabetes
Project: A System’s
Patient Care Process (2015-2016).
tion. Pharmacists’ Society
See-Won Seo
Support Group: Diabetes
Approach to Reducing
of the State of New York
Performance-Enhancing
Medications and Neurop-
the Burden of Asthma in
Annual Meeting, Rye
Drugs. Continuing Educa-
athy. January 2016.
New York State
American Association of
Brook, NY, June 2016.
tion. ACPHS, Albany, NY,
Grantor: Whitney M Young
Colleges of Pharmacy
Jr. Health Center
(AACP). Chair, Section of
Amount: $12,800
Teachers of Pharmacy
Awarded: June 2016
Practice Faculty Develop-
Sept 2016.
GRANTS
Patel N. Medication Errors in HIV. Continuing Educa-
New Drug Update.
Katie Cardone
tion. Telemedicine series
Continuing Education.
Principal Investigator:
broadcast to all New
Pharmacists Society of
Wendy M. Parker
HONORS AND
York State Department of
the State of New York
Co-Principal Investigator:
APPOINTMENTS
Corrections pharmacists,
Mid-Winter Conference,
Katie E. Cardone
Albany Medical Center
Saratoga Springs, NY,
Project: Health disparities
Jeffrey Brewer
Clinical Pharmacy (ACCP).
HIV Clinic, Albany, NY,
Jan 2016.
and medication manage-
Fellow of the American
Member, Educational
ment strategies among
Society of Health-System
Affairs Committee (2016-
Matthew Stryker
adolescents and young
Pharmacists, 2016
present).
Patel N. Updates in Epi-
Part II: Starting Non-In-
adults with Diabetes
demiology and Treatment
sulin Medication in the
Mellitus
Jacqueline Cleary
Nimish Patel
of Hepatitis C Infection.
Primary Care Setting for
Grantor: John Faunce and
2016 PAINWeek Scholar-
Society of Infectious
Continuing Education.
Type 2 Diabetes. Ameri-
Alicia Tracy Roach Fund
ship Recipient
Diseases Pharmacists:
ACPHS, Albany, NY, Feb-
can Diabetes Association
Amount: $24,943.36
ruary 2016.
– Innovations in Diabetes
June 2016.
ment Committee (Chair2016-present). American College of
Impact Paper of the Year Gina Garrison
Care Annual Meeting,
Thomas Lodise
National Secretary, Rho
Sarah Peters
Patel N. Updates in Epide-
Troy, NY, November 10,
Project: Antibacterial
Chi Academic Honor
President, Hematology/
miology and Treatment of
2016.
Resistance Leadership
Society, 2011-present
Oncology Pharmacy
HIV. Continuing Education.
Association, 2016-17
Group: Minocycline PK in
ACPHS, Albany, NY, Feb-
Alexandra Watson
IC Patients
Nicole Lodise
ruary 2016.
Watson A. Comprehen-
Grantor: Duke Universi-
American Association of
sive Primary Care (CPC)
ty, National Institute of
Colleges of Pharmacy
Joanna Schwartz
Leading Innovation,
Allergy and Infectious
(AACP). Member, Tobacco
Schwartz J. Oral che-
Inspiring Engagement.
Diseases (NIAID)
Control Committee, Public
motherapy safety and
New York Region Full Day
Amount: $35,802
Health Special Interest
adherence. Northern New
Learning Session, Octo-
Term: December 1, 2016 -
Group (2016- present).
England Chapter of the
ber 2016 (panelist).
November 30, 2017
ical Oncology (NNECOS),
Watson A. CapitalCare
Michael Kane, Matthew
Colleges of Pharmacy
October 26, 2016, Bretton
Medical Group Diabetes
Stryker, Robert Hamilton
(AACP). Faculty Champi-
Woods, NH.
Support Group: Ask a
Project: A Real World,
on, Joint Council of Deans/
Pharmacist. September
Observational Study of
Council of Faculties “Cat-
2016.
Weekly Exenatide Added
alyst Team to Integrate
to Basal Insulin in Patients
the Joint Commission of
American Society of Clin-
Schwartz J. Assessment of
American Association of
herbal, dietary supplement and OTC medica-
Watson A. Updates on
with Type 2 Diabetes
Pharmacy Practitioners
tions with chemotherapy.
Diabetes: A Focus on
Mellitus
(JCPP) Pharmacists Pa-
University of Vermont
Guidelines and Pharma-
Grantor: AstraZeneca
tient Care Process (PPCP)”
Breast Symposium,
cotherapy. Continuing Ed-
Pharmaceuticals, LP
(2016-present).
Burlington, VT, October
ucation. ACPHS, Albany,
Amount: $67,387
4, 2016.
NY, June 2016.
Awarded: July 2016
Schwartz J. New Drug
Watson A. Life on Rota-
See-Won Seo,
(AACP). Chair, Council of
Update. Northern New
tions, APhA-ASP student
Jacqueline Cleary
Faculties - Faculty Affairs
England Chapter of the
chapter meeting, ACPHS,
Principal Investigator:
Committee (COF-FAC)
American Society of Clini-
Albany, NY, May 2016.
See-Won Seo
Workgroup on Curricular
Co-Principal Investigator:
Adoption and Integra-
American Association of Colleges of Pharmacy
cal Oncology, October 28,
36 AC P H S
PR ESI DENT’ S R EPORT SC HOLARLY AC TIV ITY REPORT
D E PARTM E NT OF PHAR MACE UTI CAL SCI E N CE S – ALBANY CAMPUS PUBLICATIONS
Musteata FM, Sandoval
Pharmacology: An Over-
ator. 2nd CNS Anticancer
Zheng HA. Trends &
M, Ruiz JM, Harrison K,
view” in Systems Pharma-
Drug Discovery/Devel-
Transformations within
McKenna D, Millington W.
cology and Pharmacody-
opment Conference
Graduate Education.
Rapid, Minimally Invasive
namics. D.E. Mager and
co-sponsored by Society
AACP Annual Meeting,
James M. Gallo
Analysis of Amazonian
H.C. Kimko, Eds., American
of Neuro-Oncology in
Anaheim, CA, July 23,
Wang T, Pickard AJ, Gallo,
Plants Using Solid Phase
Association of Pharmaceu-
association with Annual
2016 (forum organizer/
JM. Histone Methylation
Microextraction, Phyto-
tical Scientists, Springer
meeting. Phoenix, AZ,
chair).
by Temozolomide: A
chemical Fingerprinting,
(ISBN: 978-3-319-44532-
November 16-17, 2016.
Classic DNA Methylating
and LC-MS. Analytica
8), 2016.
Agent. Anticancer Re-
Chimica Acta, 933, p. 124-
search, 36:3289-99, 2016.
133, 2016.
P E E R RE V I E W E D A RT IC L E S
Zheng HA. China-US Gail Goodman-Snitkoff
Clinical Pharmacy
HaiAn Zheng
The Microbiome in Health
Experiential Education
Zheng HA, Crison J. “Drug
and Disease. Grand
Exchange (CPEEE) Pro-
Pickard AJ, Sohn AS,
Musteata FM. Making
Delivery and Product
Rounds at Ellis Hospital,
grams – Achievements,
Bartenstein TF, He S,
Sense of Vitamin D Con-
Design” in Martin’s
October 21, 2016.
Challenges & Promises.
Zhang Y, Gallo JM.
centrations. Future Sci-
Physical Pharmacy and
Intracerebral Distribution
ence OA, 2(1), doi 10.4155/
Pharmaceutical Sciences,
Marcel Musteata
of Pharmacy, Shanghai,
of the Oncometabo-
fso.15.90, 2016.
7th edition. Edited by
Mall I, Zheng HA, Mus-
May 28, 2016 (invited
Patrick Sinko, Lippin-
teata FM. Investigating
speaker).
transdermal diffusion of
lite D-2-Hydroxyglutarate
Fudan University School
in Mice Bearing Mutant
HaiAn Zheng
cott Williams & Wilkins,
Isocitrate Dehydroge-
Alsharif NZ, Abrons JP,
December 2016, ISBN,
vitamin D and 25-hy-
Mall I, Zheng HA, Mus-
nase Brain Tumors: Impli-
Williams D, Zheng HA,
9781496353443.
droxyvitamin D. Pittcon
teata FM. Investigating
cations for Tumorigene-
Ombengi DN, Dakkuri A,
2016, Atlanta, GA, March
transdermal diffusion of
sis. Frontiers Oncology,
AlDahir S, Tofade T, Gim
Wu L, Smith H, Zheng
2016 and AAPS-NERDG,
vitamin D and 25-hy-
6:211, 2016.
S, O’Connell MB. Global/
HA, Yu L. “Drug Product
Farmington, CT, April 2016
droxyvitamin D. AAPS-
International Advanced
Approval in the United
(poster presentation).
NERDG Annual Meeting,
Marcel Musteata
Pharmacy Practice
States and Internation-
Singh A, Bartiss R,
Experiences: Host Coun-
al Harmonization” in
HaiAn Zheng
Rahman T, Arabshahi
try, Site and Institution
Developing Oral Solid
Zheng HA, Teng J, Fein-
A, Prasain J, Barnes S,
Considerations. American
Dosage Forms. Academ-
berg D. Teaching a Reg-
HONORS AND
Musteata FM, Sellati TJ.
Journal of Pharmacy Edu-
ic Press, 2nd edition,
ulatory Science Course
APPOINTMENTS
Lipoxin A4, a 5-lipoxygen-
cation, 25;80(3):38. 2016
November 2016, ISBN:
Blended with eLearning
9780128024478.
Lectures and Active
James M. Gallo
Learning. AAPS Annual
Appointed Associate Edi-
CONFERENCE
Meeting, San Diego, CA,
tor, PLOS: Computational
PRESENTATIONS
November 13-17, 2016.
Biology, September 2016.
ase pathway metabolite, modulates immune
B O O K C HAP T ERS
response during acute
Farmington, CT, April
respiratory tularemia.
James M. Gallo
Journal of Leukocyte
Birtwistle MR, Hansen J,
Biology, September 14,
Gallo JM, Muppirisetty
James M. Gallo
Hawke RL, Pereira HA,
2016 (published online
S, Man-Ung P, Iyengar R,
Planning and Scientific
Allen DD, O’Barr SA,
before print).
Schlessinger A. “Systems
Committees and Moder-
Poloyac S, Tropsha A,
2016.
D E PARTM E NT OF PHAR MACE UTI CAL SCI E N CE S – VERMONT CAMPUS PUBLICATIONS P E E R RE V I E W E D A RT IC L E S
Cornilescu G, Carlson S,
the Plant Homeodomain
Subramaniam R, Jagadee-
Organic Process Research
Tonelli M, McClurg UL,
of Inhibitor of Growth
san R, Mathew I, Cen Y,
& Development (in revision).
Binda O, Robson CN, Mar-
3. Journal of Biological
Balaz S. Scalable Synthe-
kley JL, Balaz S, Glass
Chemistry 2016, 291,
sis and Purification
Yana Cen
Stefan Balaz
KC. Mechanism of Histone
18326-18341.
of Acetylated Phosphati-
Wood M, Cen Y. Facile
Kim S, Natesan S,
H3K4me3 Recognition by
dyl Choline Headgroup.
Synthesis of NaMN, NaAD
S CH O LA R LY ACT IV IT Y R EP O RT AC P H S P RE SID E N T’ S RE P O RT  37
and Derivatives. Annals of
Karen Glass
Biological Chemistry 2016,
Biology Approach for Sir-
Tamer Fandy
Pharmacology & Pharma-
Kim S, Natesan S,
291, 18326-18341.
tuin Profiling. Sixth Annual
Cen Y, Wood M, Fandy T.
ceutics, 2016, 1, 1007.
Cornilescu G, Carlson S,
ACPHS Research Forum,
DNA Hypomethylating
Tonelli M, McClurg UL,
CONFERENCE
Albany, NY, January 23,
Agents Modulate the
Subramaniam R,
Binda O, Robson CN,
PRESENTATIONS
2016 (oral presentation).
Activity of the Histone
Jagadeesan R, Mathew I,
Markley JL, Balaz S, Glass
Cen Y, Balaz S. Scalable
KC. Mechanism of Histone
Stefan Balaz
Graham E, Rymarchyk S,
6 (SIRT6). 2016 AAPS
Synthesis and Purification
H3K4me3 Recognition by
Kim S, Natesan S,
Cen Y. Design and Syn-
Annual Meeting and
of Acetylated Phosphati-
the Plant Homeodomain
Cornilescu G, Carlson S,
thesis of Activity-based
Exposition, Denver, CO,
dyl Choline Headgroup.
of Inhibitor of Growth
Tonelli M, McClurg UL,
Chemical Probes for Spe-
November 2016 (poster
Organic Process Research
3. Journal of Biological
Binda O, Robson CN, Mar-
cific Sirtuin Isoforms. Sixth
presentation).
& Development, 2017, 21,
Chemistry 2016, 291,
kley JL, Balaz S, Glass
Annual ACPHS Research
177-181.
18326-18341.
KC. Mechanism of Histone
Forum, Albany, NY,
Karen Glass
H3K4me3 Recognition by
January 23, 2016 (poster
Kim S, Natesan S,
presentation).
Cornilescu G, Carlson
Deacetylase Sirtuin
Tamer Fandy
Hassan HE, Keita JA,
the Plant Homeodomain
Gunasekara DC, Zheng
Narayan L, Brady SM,
of Inhibitor of Growth 3.
MM, Mojtahed T, Woods
Frederick R, Carlson
Keystone Symposium on
Cen Y. Novel Probes
UL, Binda O, Robson
JR, Fandy TE, Riofski MV,
S, Glass KC, Natesan
Chromatin and Epi-
for Sirtuins: a Chemi-
CN, Markley JL, Balaz
Glackin CA, Hassan HE,
S, Buttolph T, Fandy
genetics, Whistler, BC,
cal Biology Approach.
S, Glass KC. Histone
Kirshner J, Colby DA.
TE. The combination of
Canada, March 21, 2016
University of Vermont,
Recognition by the ING3
15-Methylene-Eburna-
dimethoxycurcumin with
(poster presentation).
Burlington, VT, April 2016
PHD Finger in the TIP60
monine Kills Leukemic
DNA methylation inhibitor
(invited talk).
Histone Acetyltransferase
Stem Cells and Reduces
enhances gene re-expres-
Kim S, Natesan S, Cor-
Engraftment in a Hu-
sion of promoter-methylat-
nilescu G, Carlson S, Ton-
Graham E, Rymarchyk S,
ACPHS Research Forum,
manized Bone Marrow
ed genes and antagonizes
elli M, McClurg UL, Binda
Wood M, Zhang K, Lin H,
Albany, NY, January 23,
Xenograft Mouse Model
their cytotoxic effect.
O, Robson CN, Markley JL,
Cen Y. Activity-based Sir-
2016 (Abstract).
of Leukemia. ChemMed-
Epigenetics 2016, 11,
Balaz S, Glass KC. Histone
tuin Profiling. Clinical and
Chem 2016, 11, 2392-2397.
740-749.
Recognition by the ING3
Translational Research
Lloyd JT, Gay JC, Carlson
PHD Finger in the TIP60
Symposium, University
SA, Eckenroth BE, Doublie S, Glass KC. Histone
S, Tonelli M, McClurg
Complex. Sixth Annual
Fandy TE, Abdallah I,
Senthil Natesan
Histone Acetyltransferase
of Vermont, Burlington,
Khayat M, Colby DA, Has-
Hassan HE, Keita JA,
Complex. Sixth Annual
VT, April 2016 (poster
Binding and Ligand Rec-
san HE. In vitro character-
Narayan L, Brady SM,
ACPHS Research Forum,
presentation).
ognition by the ATAD2b
ization of transport and
Frederick R, Carlson S,
Albany, NY, January 23,
metabolism of the alka-
Glass KC, Natesan
2016 (Abstract).
loids: vincamine, vinpoce-
S, Buttolph T, Fandy
tine and eburnamonine.
TE. The combination of
Cancer Chemotherapy
Bromodomain. Sixth Cen Y, Wood M, Fandy T.
Annual ACPHS Research
DNA Hypomethylating
Forum, Albany, NY,
Kim S, Natesan S, Cor-
Agents Modulate the
January 23, 2016 (poster
dimethoxycurcumin with
nilescu G, Carlson S, Ton-
Activity of the Histone
presentation).
and Pharmacology 2016,
DNA methylation inhibitor
elli M, McClurg UL, Binda
Deacetylase Sirtuin
77, 259-267.
enhances gene re-expres-
O, Robson CN, Markley JL,
6 (SIRT6). 2016 AAPS
Gay JC, Carlson SA, Glass
sion of promoter-methylat-
Balaz S, Glass KC. Mecha-
Annual Meeting and
KC. Using Isothermal
Hassan HE, Keita JA,
ed genes and antagonizes
nism of Histone H3K4me3
Exposition, Denver, CO,
Calorimetry to Determine
Narayan L, Brady SM,
their cytotoxic effect.
Recognition by the Plant
November 2016 (poster
ATAD2b Histone Binding
Frederick R, Carlson
Epigenetics 2016, 11,
Homeodomain of Inhibitor
presentation).
Affinities. Sixth Annual
S, Glass KC, Natesan
740-749.
of Growth 3. University of
S, Buttolph T, Fandy
ACPHS Research Forum,
Vermont Cancer Center
Tran A, French J, Cen Y.
Albany, NY, January 23, 2016 (poster presentation).
TE. The combination
Kim S, Natesan S, Cor-
Clinical and Translational
Design and Synthesis of
of dimethoxycurcumin
nilescu G, Carlson S, Ton-
Research Symposium, Bur-
Dual-functional Nucleo-
with DNA methylation
elli M, McClurg UL, Binda
lington, VT, April 29, 2016
base Analogs for Labeling
Kim S, Natesan S,
inhibitor enhances gene
O, Robson CN, Markley JL,
(poster presentation).
Nucleobase Transporters.
Cornilescu G, Carlson S,
re-expression of promot-
Balaz S, Glass KC. Mecha-
2016 ACPHS Student Sum-
Tonelli M, McClurg UL,
er-methylated genes and
nism of Histone H3K4me3
Yana Cen
mer Research Presentation
Binda O, Robson CN,
antagonizes their cyto-
Recognition by the Plant
Graham E, Wood M,
and Award Ceremony, Al-
Markley JL, Balaz S, Glass
toxic effect. Epigenetics
Homeodomain of Inhibitor
Rymarchyk S, Zhang K,
bany, NY, November 2016
KC. Mechanism of Histone
2016, 11, 740-749.
of Growth 3. Journal of
Lin H, Cen Y. Chemical
(poster presentation).
H3K4me3 Recognition by
38 AC P H S
PR ESI DENT’ S R EPORT SC HOLA RLY AC TIV ITY REPORT
PATENTS
the Plant Homeodomain
S, Glass KC. Histone
Research Presentations
UL, Binda O, Robson
of Inhibitor of Growth 3.
Binding and Ligand Rec-
and Honors and Awards
CN, Markley JL, Balaz
Keystone Symposium on
ognition by the ATAD2b
Ceremony, Albany, NY,
S, Glass KC. Histone
Yana Cen
Chromatin and Epi-
Bromodomain. University
November 12, 2016
Recognition by the ING3
Sauve AA, Cen Y. “Re-
genetics, Whistler, BC,
of Vermont Cancer Center
(poster presentation).
PHD Finger in the TIP60
agents and Methods for
Canada, March 21, 2016
Clinical and Translational
Histone Acetyltransferase
Sirtuin Capture”, U.S. Pat-
(poster presentation).
Research Symposium, Bur-
Senthil Natesan
Complex. Sixth Annual
ent No. 9,290,791, March
lington, VT, April 29, 2016
Kim S, Natesan S,
ACPHS Research Forum,
22, 2016.
(poster presentation).
Cornilescu G, Carlson S,
Albany, NY, January 23,
Tonelli M, McClurg UL,
2016 (Abstract).
Kim S, Natesan S, Cornilescu G, Carlson S, Ton-
GRANTS
elli M, McClurg UL, Binda
Gay JC, Carlson SA, Glass
Binda O, Robson CN, Mar-
O, Robson CN, Markley JL,
KC. Using Isothermal
kley JL, Balaz S, Glass
Kim S, Natesan S, Cor-
Karen Glass
Balaz S, Glass KC. Mecha-
Calorimetry to Determine
KC. Mechanism of Histone
nilescu G, Carlson S, Ton-
Project: Mechanisms of
nism of Histone H3K4me3
ATAD2b Histone Binding
H3K4me3 Recognition by
elli M, McClurg UL, Binda
Chromatin Binding and
Recognition by the Plant
Affinities. University of
the Plant Homeodomain
O, Robson CN, Markley JL,
Selection by Family IV
Homeodomain of Inhibitor
Vermont Cancer Center
of Inhibitor of Growth 3.
Balaz S, Glass KC. Mecha-
Bromodomains
of Growth 3. University of
Clinical and Translational
Keystone Symposium on
nism of Histone H3K4me3
Grantor: National
Vermont Cancer Center
Research Symposium, Bur-
Chromatin and Epi-
Recognition by the Plant
Institutes of Health (R15
Clinical and Translational
lington, VT, April 29, 2016
genetics, Whistler, BC,
Homeodomain of Inhibitor
renewal)
Research Symposium, Bur-
(poster presentation).
Canada, March 21, 2016
of Growth 3. University of
Amount: $384,000
(poster presentation).
Vermont Cancer Center
Term: February 1, 2016 –
Clinical and Translational
January 31, 2019
lington, VT, April 29, 2016 (poster presentation).
Evans C, Gay J, Glass KC. Functional charac-
Kim S, Natesan S,
Research Symposium, Bur-
Lloyd JT, Gay JC, Carlson
terization of the BPRF3
Cornilescu G, Carlson
lington, VT, April 29, 2016
SA, Eckenroth BE, Doublie
bromodomain. Summer
S, Tonelli M, McClurg
(poster presentation).
SCHOOL OF ARTS AND SCIENCES D E PARTM E NT OF BA S I C AN D CLI N I CAL SCI E N CE S PUBLICATIONS Sean Ali
Journal of Quantum
py Method to the Physics
123, published online on 1
Christopher Cioffi
Information, 2016, 14
of Ferromagnetic
November 2016.
Cioffi CL, Liu S, Wolf MA,
(3); 1630003.
material. Physica A, 2016, 455; 11-26.
Cafaro C, Ali SA. Maxi-
Guzzo PR, Sadalapure K, Siedlik JA, Bergeron C,
Parthasarathy V, Loong
Cooper MA, Emmons R,
DT, J.; Maeng J-H, Carulli
mum caliber inference
Cafaro C, Ali SA, Giffin A.
and the stochastic Ising
Thermodynamic Aspects
Charles Bergeron
Moreau W, Nabhan D,
E, Fang X, Kalesh KA,
model. Physical Review E,
of information Transfer
Boles NC, Stone T,
Gallagher P, Vardiman
Matta L, Choo SH, Pan-
2016, 94 (5); 052145.
in Complex Dynamical
Bergeron C, Kiehl TR. Big
JP. Advanced treatment
duga S, Buckle RN, Davis
Systems. Physical Review
Data Access and Infra-
monitoring for athletes
RN, Sakwa SA, Gupta
E, 2016, 93 (2); 022114.
structure: Case Studies in
using unsupervised mod-
P, Sargent BJ, Moore
Data Repository Utility.
eling techniques. Journal
NA, Luche MM, Carr GJ,
Cafaro C, Ali SA, Giffin A. On the Violation of Bell’s Inequality for all
Cafaro C, Giffin A, Ali
Annals of the New York
of Athletic Training 51(1),
Khmelnitsky YL, Ismail J,
non-Product Quantum
SA. Application of the
Academy of Sciences,
74-81.
Chung M, Bai M, Leong
States. International
maximum Relative Entro-
Volume 1387, pages 112-
WY, Sachdev N, Swamina-
S CH O LA R LY ACT IV IT Y R EP O RT AC P H S P RE SID E N T’ S RE P O RT 39
than S, Mhyre AJ. Synthe-
Molecular Microbiology,
Furuya AKM, Sharifi HJ,
Stone T, Kiehl TR,
NY, May 23, 2016 (invited
sis and Biological Evalu-
101(5):856-78. Sept. 2016.
Jellinger RM, Cristofano
Bergeron C. Cutting
oral presentation).
P, Shi B, de Noronha CMC
through the spatial scale
ation of N-((1-(4-(Sulfonyl) piperazin-1-yl)cycloalkyl)
Rabadi SM, Sanchez BC,
(2016). Sulforaphane
complexity of multielec-
LaRocca TJ, Sosunov SA,
methyl) benzamide
Varanat M, Ma Z, Catlett
Inhibits HIV Infection of
trode array neuron record-
Shakerley NL, Ten VS,
Inhibitors of Glycine
SV, Melendez JA, Malik
Macrophages through
ings. New York Academy
Ratner AJ. High glucose
Transporter-1. Journal of
M, Bakshi CS. Antioxidant
Nrf2. PLoS Pathogens
of Sciences Symposium
sensitizes host cells to
Medicinal Chemistry 2016,
defenses of Francisella
12(4): e1005581.
on Neuronal Connectivity
necroptosis in response
59; 8473-8494.
tularensis modulate
in Brain Function and Dis-
to bacterial pore-forming
macrophage function and
Ebot Tabe
ease: Novel Mechanisms
toxins and inflammatory
Cioffi CL, Guzzo PR. Inhibi-
production of proinflam-
Tabe N, Rahman S, Tabe
and Therapeutic Target,
signals. ASM Microbe
tors of Glycine Transport-
matory cytokines. Journal
ES, Doetkott D, Khaitsa M
New York City, NY, March
General Meeting, Boston,
er-1: Potential Therapeu-
of Biological Chemistry,
(2016). Shigatoxin produc-
22, 2016 (abstract and
MA, June 16-20, 2016
tics for the Treatment of
291(10):5009-21.
ing Escherichia coli and
poster presentation)
(poster presentation).
CNS Disorders. Current
March 2016.
Salmonella spp burden in cattle feedlot runoff from
James Doyle
Shakerley NL, Craft M,
Michael Racz
two cattle feedlot facili-
Doyle J, Teng J.
Smiraglia TA, Payal
Hannan EL, Racz MJ,
ties. North Dakota Food
Cyber-CYP: A Student
PS, Sosunuv S, Ten VS,
Cioffi C, Petrukhin KE,
Walford G, Jacobs AK,
Protection Trends, Vol 36,
Self-Directed Interactive
LaRocca TJ. Hyperglyce-
Johnson G. Recent devel-
Stamato NJ, Gesten F,
No. 1, pp. 33-42.
Tool for Learning Cyto-
mia primes cells for pro-
opments in agents for the
Berger PB, Sharma S, King
chrome P450. EdMedia
grammed cell death shift
treatment of age-related
SB 3rd, (2016). Disparities
Eric Yager
2016 Conference, Van-
in a glycolysis-dependent
macular degeneration
in the use of drug-eluting
Kohlmeier JE, Ely KH,
couver, BC, June 29, 2016
manner. 22nd Society
and Stargardt disease.
coronary stents by race,
Connor LM, Yager EJ,
(oral presentation).
for Radical Biology and
2016 Medicinal Chemistry
ethnicity, payer and hos-
Woodland DL, Black-
Reviews, 51, chapter 16;
pital. Canadian Journal of
man MA. Beneficial and
Peter R. Guzzo
Francisco, CA, Novem-
261-278.
Cardiology, 32(16): 987.
detrimental manifestations
Guzzo PR. ConSynance:
ber 16-19, 2016 (poster
e25-987.e31.
of age on CD8+ T-cell
An Emerging Drug Dis-
presentation).
memory to respiratory
covery Company. Capital
Topics in Medicinal Chemistry 2016, 16; 3404-3437.
Timothy LaRocca
Medicine Meeting, San
LaRocca TJ, Sosunov SA,
H. John Sharifi
pathogens. Handbook on
Region Biotechnology
Shakerley, NL, Smiraglia
Shakerley NL, Ten VS,
Furuya AKM, Sharifi HJ,
Immunosenescence: Basic
Innovation Day, Troy, NY,
TA, Patel PS, Walker KM,
Ratner AJ. Hyperglycemic
Jellinger RM, Cristofano
Understanding and Clinical
September 16, 2016.
Craft M, Sosunov SA, Ten
conditions prime cells for
P, Shi B, de Noronha CMC
Applications, Eds. T. Fulop,
RIP1-dependent necropto-
(2016). Sulforaphane
C. Franceschi, K. Hirokawa
Guzzo PR. Novel Thera-
glycemia potentiates a
sis. Journal of Biological
Inhibits HIV Infection of
and G. Pawelec. Springer
peutics for Inflammatory
shift from apoptosis to
Chemistry, June 2016,
Macrophages through
Netherlands, 2016.
Bowel Disease and Irrita-
necroptosis. Eastern New
291(26): 13753-61.
Nrf2. PLoS Pathogens
ble Bowel Syndrome. BIO
York Student Chapter of
International Convention,
the American Society for
San Francisco, CA, June
Microbiology, Albany, NY,
7, 2016.
November 17, 2016 (poster
12(4): e1005581.
PRESENTATIONS
LaRocca TJ. Programmed
VS, LaRocca TJ. Hyper-
cell death dynamics
Binshan Shi
Charles Bergeron
during hyperglycemia
Watanabe S, Simon V,
Bergeron C, Stone T,
and ischemic brain inju-
Kemp B, Machihara S,
Kiehl TR. A pipeline for a
Guzzo PR. Novel Ther-
ries. Journal of Neurology
Kemal K, Shi B, Foley B,
growing data resource:
apeutics for Inflamma-
Jenna LeBlanc
and Neurorehabilitation
Weiser B, Burger H, Anas-
Electrophysiological
tory Bowel Disease and
Envision Your Value,
Research, Nov 2016,
tos K, Chen C, Carter C.
behavior of in-vitro cell
Irritable Bowel Syndrome.
Advocate for the Future.
1(2): 4-12.
The HIV-1 Late Domain-2
cultures. Meeting of the
New York BIO Conven-
American Society of
S40A Polymorphism in
National Science Foun-
tion, New York City, NY,
Cytopathology Annual
Meenakshi Malik
Antiretroviral (or ART)-
dation Workshop on Data
May 11, 2016.
Scientific Meeting,
Ma Z, Russo VC, Rabadi
Exposed Individuals
Science, Learning, and
SM, Catlett SV, Bakshi
Influences Protease
Applications to Biomedi-
Timothy LaRocca
CS, Malik M. Elucidation
Inhibitor Susceptibility.
cal and Health Sciences,
LaRocca TJ. Hyperglyce-
of the Mechanism of Oxi-
Retrovirology, 2016;
New York City, New York,
mia upregulates necro-
Meenakshi Malik
dative Stress Regulation
13(1):64.
Jan 7-8, 2016.
ptosis. Long Island Uni-
Oliva G, Shah R, Lu J,
versity Post, Brookville,
Catlett SV, Pai MP, Rose
in Francisella tularensis.
presentation).
New Orleans, LA, November 2016.
40 AC P H S
PR ESI DENT’ S R EPORT SC HOLARLY AC TIV ITY REPORT
WE, Sakoulas G, Malik
Michael Racz
Science, August 1-4, 2016,
Grantor: National Insti-
M. Characterization of
Gumustop S, Nair AA,
Philadelphia, PA (oral
tutes of Health
gene expression in
Meek PD, Racz MJ,
presentation).
(R15 renewal)
Guzzo PR, Surman MD,
profile associated with
O’Grady TJ, Gumustop
Amount: $480,000
Henderson AJ, Jiang, MX,
daptomycin nonsuscep-
B. Regional patterns of
Ebot Tabe
Term: December 1, 2016 –
Hadden M, Grabowski
tibility in Staphylococcus
pancreatectomy case
Tabe E. A Salicylate
November 30, 2019
J. 1-Azinone-substituted
aureus. Poster presented
volumes and in-hospital
Derivative-Enhanced
in 116th General Meeting
mortality in New York
Antimicrobial Activity of a
Project: Modeling the
No. 9,296,743: March 29,
of American Society for
State between 1999-2014.
Synthetic Peptide against
emergence of antimicrobi-
2016.
Microbiology, Boston, MA,
Digestive Disease Week,
Pseudomonas aeruginosa
al resistance
June 16-19, 2016.
May 2016, San Diego, CA
in-vitro. Public Health
Role: Co-Principal
Jenna LeBlanc
(poster presentation).
and Emerging Microbial
Investigator
President Elect,
Threats 14th Annual
Grantor: Wadsworth
American Society for Cytotechnology
Ma Z, Russo V, Rabadi
May 31, 2016.
pyridoindoles. U.S. Patent
SM, Catlett SV, Bakshi
Nair AA, Gumustop SB,
International Conference,
Center and ACPHS
CS, Malik M. Elucidation
Racz MJ, O’Grady TJ,
September 19, 2016, Alba-
Amount: $375,000
of the mechanism of ox-
Polimeni JM, Gumustop
ny College of Pharmacy
Term: February 16, 2016 –
Nicole Shakerley
idative stress regulation
B, Meek PD. Temporal
and Health Sciences,
February 15, 2019
Young Investigator
in Francisella tularensis.
trends in utilization of
Albany, NY.
Poster presented in
pancreatectomy proce-
116th General Meeting
dures in New York State:
of American Society for
1999-2014. International
Microbiology, Boston, MA,
Society for Pharmacoeco-
Timothy LaRocca
Peter R. Guzzo (Patents)
Binshan Shi
June 16-19, 2016.
nomics and Outcomes
Project: Mechanisms and
Kharenko O, Young PR,
Winning Research Paper
Research 21st Annual
outcomes of erythrocyte
Brown SD, Duffy BC, Liu
at 2016 Education Scien-
Marghani D, Ma Z, Malik
International Meeting,
necroptosis
S, Guzzo PR. Inhibitors
tific Assembly Student
M, Bakshi CS. Charac-
May 2016, Washington,
Grantor: National Insti-
of bromodomains.
Awards competition (with
terization of the role of
DC (poster presentation).
tutes of Health
WO 2016/097863,
Michaela Kinnetz)
Amount: $480,000
June 23, 2016.
Transcriptional Regulator
GRANTS
AraC of Francisella tula-
Binshan Shi
Term: December 1, 2016 –
rensis. Poster presented
Kinnetz M, Shi B. The
November 30, 2019
in 116th General Meeting
Inhibition of Retrovirus
of American Society for
Reverse Transcription
Microbiology, Boston, MA, June 16-19, 2016.
Award from the Society
HONORS AND
for Radical Biology
APPOINTMENTS
and Medicine
Ebot Tabe Guzzo PR, Manning DD.
Young Scholar Award
Ligand-therapeutic agent
from Dova Press on the
Meenakshi Malik
conjugates, silicon-based
occasion of the 14th an-
by p53. Annual Meeting
Project: Repression of
linkers, and methods for
nual conference on Public
of the American Society
inflammasome by Fran-
making and using them.
Health and Emerging
for Clinical Laboratory
cisella tularensis
U.S. Patent No. 9,352,049:
Microbial Threats.
D E P A R T M E N T O F P O P U L AT I O N H E A LT H S C I E N C E S PUBLICATIONS
Katz LH, Burton-Chase
Silvera SAN, Bur-
Epidemiology, Biomarkers
Rogith D, Yusuf RA, Hov-
AM, Advani S, Fellman
ton-Chase AM, Phillips
& Prevention (in press).
ick SR, Fellman BM, Pe-
Allison M. Burton-Chase
F, Polivka KM, Ying Y,
L, Thompson CL, Stolley
Burton-Chase AM, Parker
Lynch PM, Pande M,
M, Chang S. Creating
Burton-Chase AM, Kwak
AM, Li Y, Bernsam EV,
WM, Hennig K, Sisson F,
Peterson SK. Screening
and managing a work/
J, Hennig K, Haley WE.
Meric-Bernstam F. (2016)
Bruzzone L. The use of
adherence and cancer
life balance as a junior
Elder Caregiving. In
Patient knowledge and
social media to recruit
risk perceptions in
investigator in the aca-
Reference Module of
Information seeking about
participants with rare
family members of
demic environment – A
Neuroscience and
personalized cancer ther-
conditions: Lynch syn-
colorectal cancer survi-
report from the American
Biobehavioral Psycholo-
apy. International Journal
drome as an example.
vors with Lynch-like
Society of Preventive On-
gy. New York: Elsevier
of Medical Informatics, 88;
JMIR Research Protocols
syndrome. Familial Can-
cology’s Junior Members
(in press).
52-57.
(in press).
cer (in press).
Interest Group. Cancer
terson SK, Burton-Chase
S CHO LA R LY ACT IV IT Y R EP O RT AC P H S P RE SID E N T’ S RE P O RT 41
PRESENTATIONS
Effects of education and
es in recruiting patients
Nair AA, Gumustop SB,
AM, Advani S, Fellman F,
other socioeconomic vari-
for medication therapy
Racz MJ, O’Grady TJ,
Polivka K, Ying Y, Lynch
Allison M. Burton-Chase
ables on HIV seroprev-
management (MTM): How
Polimeni JM, Gumustop B,
PM, Pande M, Peterson
Hennig K, Chu R, DeCoster
alence in Russia, India,
to address patient resis-
Meek PD. Temporal trends
SK. (2016) Screening ad-
B, LeBorgne A, Parker
South Africa, and the
tance to participating in
in utilization of pancre-
herence and cancer risk
WM, Campo-Engelstein L,
United States of America.
MTM. Presented at the 3rd
atectomy procedures in
perceptions in colorectal
Burton-Chase, AM. The im-
Poster presented at the
Annual ACPHS Student
New York State: 1999-
cancer survivors with
pact of care coordination
21st Annual International
Research Symposium
2014. Poster presented
Lynch-like syndrome.
on provider satisfaction in
Meeting of the Interna-
at Albany College of
at International Society
Clinical Genetics, 89 (3);
Lynch syndrome survivors
tional Society for Pharma-
Pharmacy and Health
for Pharmacoeconomics
392-398.
and previvors. Poster
coeconomics Research
Sciences, April 2016.
and Outcomes Research
presented at the Albany
(ISPOR), Washington, DC,
Wendy Parker
College of Pharmacy and
May 2016.
Polimeni JM, Iorgulescu
Health Sciences Student
RI, Almalki A, Albu L,
Summer Research Award
Parker WM, Donato
macists’ perspectives on
Parker WM, Chandrase-
Day, Albany, NY,
KM, Burton-Chase AM.
challenges and strategies
Wendy Parker
kara R. (2016) Assessment
November 2016.
Preventive screening and
of patient-centered com-
DeCoster B, Parker WM.
risk for women with Lynch
munication. Presented at
Alliances in Women’s
Katz LH, Burton-Chase
of Macro-level Socioeco-
21st Annual International Yehia A, Denvir P.
Meeting, Washington, DC,
Adherence talk: Phar-
May 2016.
nomic Factors that Impact
Burton-Chase AM, Hennig
syndrome: Initial results
the 6th Annual ACPHS
Health: Our Bodies,
Waterborne Diseases:
K, LeBorgne A, Chu R,
of a case-control study.
Research Forum at Alba-
Ourselves. Invited pre-
The Case of Jordan.
Campo-Engelstein L,
Poster presented at the
ny College of Pharmacy
sentation at Rensselaer
International Journal of
Parker WM. The impact
4th Annual Capital District
and Health Sciences,
Polytechnic Institute’s
Environmental Research
of care coordination on
Feminist Studies Consor-
January 2016.
Colloquium, Science, and
and Public Health.
provider satisfaction in
tium Conference, Albany,
13(12):1181. doi: 10.3390/
Lynch syndrome survivors
NY, January 2016.
ijerph13121181.
and previvors. Poster
Technology Studies DeThomas O’Grady
partment, March 9, 2016.
Chikermane S, Polimeni J,
presented at the 20th
Paul Denvir
Burton-Chase AM, Chan-
Parker WM. Health Dis-
Parker WM, Ferreira K,
Annual Meeting of the
Williams I, Denvir P. I
drasekara R, O’Grady T.
parities. Invited presen-
Vernon L, Cardone KE.
Collaborative Group of
Didn’t Want Them to Tear
Effects of education and
tation at Albany Medical
(2016) The Delicate Bal-
the Americas on Inher-
Apart Everything I Said:
other socioeconomic vari-
College, Health Care and
ance of Keeping It All
ited Colorectal Cancer
Patient and Provider
ables on HIV seroprev-
Society Course, 2016.
Together: Using Social
(CGA-ICC), Seattle, WA,
Perspectives on Sexual
alence in Russia, India,
Capital to Manage
October 2016.
Assault Disclosure. Pre-
South Africa, and the
Parker WM, DeCoster B.
sented at North American
United States of America.
Archives of the Women’s
Multiple Medications for Patients on Dialysis.
Hennig K, Chu R,
Primary Care Research
Poster presented at the
Health Movement and the
Research in Social and
DeCoster B, LeBorgne A,
Group (NAPCRG) Annual
21st Annual International
Boston Women’s Health
Administrative Pharmacy,
Parker WM, Campo-En-
Meeting, November 2016.
Meeting of the Interna-
Collective: Evidence of
S1551-7411(16)30312-
gelstein L, Burton-Chase
tional Society for Pharma-
virtues for seeking and
6. PMID: 27567742
AM. The impact of care
Williams I, Denvir P.
coeconomics Research
building alliances in
DOI: 10.1016/j.sa-
coordination on provider
Survivors’ disclosure
(ISPOR), Washington, DC,
healthcare. Presentation
pharm.2016.07.008.
satisfaction in Lynch
of sexual assault to
May 2016.
at the Association for
syndrome survivors
health care providers: A
Campo-Engelstein L,
and previvors. Poster
pilot study on disclosure
Gumustop S, Nair AA,
Washington DC, October
Santacrose LB, Master Z,
presented at the 20th
barriers and consequenc-
Meek PD, Racz MJ,
6-9, 2016.
Parker WM. (2016) Bad
Annual Meeting of the
es. Presented at the 3rd
O’Grady TJ, Gumustop
Moms and Blameless
Collaborative Group of
Annual ACPHS Student
B. Regional patterns of
Aziz R, Darivelmula S, Raf-
Dads: The Portrayal of
the Americas on Inher-
Research Symposium
pancreatectomy case
faele J, Bhatia R, Parker
Maternal and Paternal
ited Colorectal Cancer
at Albany College of
volumes and in-hospital
WM, Campo-Engelstein
Age and Preconception
(CGA-ICC), Seattle, WA,
Pharmacy and Health
mortality in New York
L. Freezing Fertility or
Harm in U.S. Newspapers.
October 2016.
Sciences, April 2016.
State between 1999-2014.
Freezing False Hope? A
Poster presented
Content Analysis of the
American Journal of Bio-
Bioethics and Humanities,
ethics: Empirical Bioethics,
Chikermane S, Polimeni J,
Adamec A, Courtney K,
at Digestive Disease
Portrayal of Social Egg
7(1): 56-63. DOI:10.1080/2
Burton-Chase AM, Chan-
Donato KM, Denvir P.
Week, San Diego, CA,
Freezing in the US Print
3294515.2015.1053007.
drasekara R, O’Grady T.
Communication challeng-
May 2016.
Media. Presentation at the
42 AC P H S
PR ESI DENT’ S R EPORT SC HOLARLY AC TIV ITY REPORT
Association for Bioethics
cal Meeting, Boston, MA,
ciology of Reproduction,
District Feminist Studies
Competency and Health
and Humanities, Washing-
April 2016.
March 17-20, 2016.
Conference, Troy, NY,
Literacy Task Force
ton DC,
January 2016.
GRANTS
Parker WM, DeCoster B.
Aziz R, Darivelmula S, Raf-
Archives of the Women’s
faele J, Bhatia R, Parker
HONORS AND
Parker WM, Donato KM,
Health Movement and
WM, Campo-Engelstein
APPOINTMENTS
Nnani D, Grabe D.
the Boston Women’s
L. Freezing Fertility or
Disparities in Hyperten-
Health Collective:
Freezing False Hope? A
Allison M. Burton-Chase
Wendy M. Parker
sion Among Women:
Evidence of virtues for
Content Analysis of the
Top-Rated Poster Award,
Co-Principal Investigator:
Exploring Social, Econom-
seeking and building
Portrayal of Social Egg
Collaborative Group of
Katie E. Cardone
ic and Health-Related
alliances in healthcare.
Freezing in the US Print
the Americas on Inherited
Project: Health disparities
Risk Factors. Concordium
Presentation at Eastern
Media. Poster presented
Colorectal Cancer (CGA-
and medication manage-
2016, Crystal City, VA,
Sociological Society
at Capital District Femi-
ICC) Annual Meeting,
ment strategies among
September 11-12, 2016.
mini-conference on
nist Studies Conference,
October 2016
adolescents and young
the Sociology of
Troy, NY, January 2016.
October 6-9, 2016.
Wegrzyn NM, Parker WM,
Reproduction,
Pai AB, Daoui R, Daoui
March 17-20, 2016.
S, Cardone, KE. Health
Wendy Parker Principal Investigator:
adults with Diabetes Vice Chair, Early Career
Mellitus
Parker WM, Donato
Special Interest Group,
Grantor: John Faunce and
KM, Burton-Chase AM.
American Society of Pre-
Alicia Tracy Roach Fund
ventive Oncology
Amount: $24,943.36
Literacy and Self-Man-
DeCoster B, Parker WM.
Preventive screenings
agement of Medications
Alliance Building in
and risks for women
Among Patients at an
Women’s HealthCare. Pre-
with Lynch syndrome:
Member, Medical Adviso-
John Polimeni
Outpatient Nephrology
sentation at Association
Initial results from a
ry Board, Alive and Kickn
Project: An Annotated
Office. Poster presented
for Practical and Profes-
case-control study. Post-
Colorectal Cancer Patient
Bibliography of Calculat-
at Academy Health,
sional Ethics, February
er presented at Capital
Advocacy Organization
ing Economic Rent
Boston, MA, June 2016.
18-21, 2016.
District Feminist Studies
Grantor: Robert Schalken-
Conference, Troy, NY,
Paul Denvir
bach Foundation
January 2016.
Chair, Language and So-
Amount: $500
cial Interaction Division of
Term: June 1, 2016 August 31, 2016
Wegrzyn NM, Parker
O’Neil G, Parker WM.
WM, Pai AB, Daoui R,
Behind the Bump:
Hogan-Moulton A,
Women’s Decision
O’Neil G, Parker WM. Be-
National Communication
Cardone KE. Assess-
Making and Expectations
hind the Bump: Women’s
Association
ing health literacy in
of Assisted Reproduction.
Decision Making and
outpatient nephrology
Presentation at Eastern
Expectations of Assisted
Wendy Parker
patients. National Kidney
Sociological Society
Reproduction, Poster
Member, Alliance for Bet-
Foundation Spring Clini-
mini-conference on the So-
presented at Capital
ter Health Care, Cultural
D E P A R T M E N T O F H U M A N I T I E S A N D C O M M U N I C AT I O N PUBLICATIONS P E E R RE V I E W E D A RT IC L E S
Questions, 1913-1924. Nor-
Rose Hitt
Smith SW, Hitt R, Park
Hitt R, Perrault E, Smith S,
dic Irish Studies Journal,
Smith S, Hitt R, Russell J,
HS, Walther JB, Liang
Keating D, Nazione S,
Vol. 14, 2015, pp. 111-126.
Silk K, Nazione S, Atkin C,
J, Hseih G. An Effort to
Silk K, Russell J. (2016).
Keating D. Risk Belief and
Increase Organ Donor
Scientific message
Margaret Carroll
Barry DeCoster
Attitude Formation From
Registration through
translation and the Heu-
Carroll M. Lough Foyle
DeCoster B, Campo-En-
Translated Scientific
Intergroup Competition
ristic Systematic Model:
Naval Air Station: WWI
gelstein L. Expedited
Messages About PFOA,
and Social Media: A Study
Insights for designing
Memories. Donegal Annu-
Partner Therapy: Clinical
an Environmental Risk
of Two College Campus
educational messages
al, 2016, No. 68.
Considerations and Public
Associated With Breast
Organ Donation Chal-
about progesterone and
Health Explorations. AMA
Cancer. Health Commu-
lenge Campaigns. Journal
breast cancer risks. Jour-
Carroll M. Martin Glynn’s
Journal of Ethics 18, no. 3
nication, doi:10.1080/1
of Health Communication
nal of Cancer Education,
Newspaper Editorials:
(March 1, 2016): 215–28.
0410236.2016.1138350
(published online,
31, 389-936. doi: 10.1007/
Constructing Albany’s
(published online,
January 2016).
s13187-015-0835-y.
Answers to the Irish
May 2016).
S CH O LA R LY ACT IV IT Y R EP O RT AC P H S P RE SID E N T’ S RE P O RT 43
Michael Pittman Pittman M. Through the Lens of Gurdjieff: Glimpses
PRESENTATIONS P O ST E R P RESE NTAT I O NS
of Contemporary Sufism in Turkey. Fieldwork in Reli-
Denise L. Coblish
gion, Vol 11, No. 1 (2016).
Preparing Your Writing
Carroll M. Lady Gregory’s
apply. International
and the Diaspora,” City
“The Rising of the Moon,”
Association for the Study
College of New York and
a critical introduction.
of Irish Literatures, Cork,
Columbia University, April
Irish American Heritage
Ireland, July 25-31, 2016.
1, 2016 (Podium Presentation).
Museum, February 2016. Barry DeCoster
Center for the Next Wave
Barry DeCoster
DeCoster B. Is ‘Demedi-
Rose Hitt
of International Students.
DeCoster B. The Social
calization’ Possible as a
Hitt R, Zuang J, Anderson
National Association for
Determinants of Health
Goal for Feminist Health?
J. Breastfeeding Beliefs:
Kenneth Blume
Development Education
and Medicalization.
Feminist Epistemology,
Content Analysis of
Brad K. Berner. The
(NADE) Annual Con-
Health, Care, and Society
Metaphysics, Methodolo-
Newspaper Coverage.
Spanish-American War. A
ference, Anaheim, CA,
first year medical student
gies, and Science Studies
Annual Meeting of the
Documentary History with
March 17, 2016.
course at Albany Medical
Conference, South Bend,
National Communication
College, Feb 10, 2016.
IN, October 2-4, 2016
Association, Philadelphia,
(paper presentation).
PA, November 2016.
RE V IE W A RT I CL E S
Commentaries. (Fairleigh Dickinson University Press, 2014), for Interna-
I NVI T ED P RESE NTAT I O NS
DeCoster B, Parker W. Alliance Building in
DeCoster B, Campo-En-
Hitt R, Zuang J, Anderson
Margaret Carroll
Women’s Healthcare.
gelstein L. Good Public
J. Breastfeeding topics in
Carroll M. Dylan Thomas:
Association for Practical
Health Policy or Sexual
U.S. newspapers. Annual
Renata E. Long. In the
An Introduction. Lecture
and Professional Ethics,
Minority Exclusion? Re-
Meeting of the National
Shadow of the Alabama.
delivered before a
Washington, DC, Febru-
thinking Expedited Part-
Communication Associ-
The British Foreign office
reading of “A Child’s
ary 20, 2016.
ner Therapy. American
ation, Philadelphia, PA,
and the American Civil
Christ-mas in Wales,”
Society for Bioethics and
November 2016.
War (Naval Institute
Irish American Heritage
Kevin Hickey
Humanities, Washington
Press, 2015), for Naval
Museum, Albany, NY,
Hickey K. Walking with
DC, October 6-9, 2016
Michael Pittman
Historical Foundation,
December 2, 2016.
Abel: Journeys with the
(paper presentation).
Influences in Contem-
tional Journal of Maritime History. May 2016.
porary Spirituality: The
Nomads of the African
Naval History Book Carroll M. Albany’s
Savannah by Anna Bad-
DeCoster B. Is ‘Demedi-
Cultural, Religious, and
Catholics in a Protestant
khen. Friends of Albany
calization’ Possible as
Spiritual Roots of G.I.
Stewart Gordon. A History
Republic. Researching
Public Library Book Re-
a Goal for Feminist
Gurdjieff in the Caucasus
of the World in Sixteen
New York Conference,
view Series, Albany, NY,
Health? American Society
and Anatolia. American
Shipwrecks (University
Albany, NY, November
June 14, 2016.
for Bioethics and Human-
Academy of Religion
Press of New England,
17-19, 2016.
ities, Washington, DC,
Regional Conference
Hickey K. Chair of “Music
October 6-9, 2016
(North Eastern-Maritimes
(paper presentation).
Region), Boston College
Reviews, Feb. 2016.
2015), for Steamship Historical Society Power
Carroll M. Alice McDer-
and Art as a Force of Po-
Ships, Spring 2016.
mott’s Someone. New
litical Expressivity.” 41st
England Regional Amer-
Annual New York African
DeCoster B, Parker W. Vir-
istry, Boston, MA,
J. Daniel d’Oney
ican Conference of Irish
Studies Association Con-
tues for Seeking Alliances
April 2, 2016.
“Hubs of Empire: The
Studies, Cape Cod, MA,
ference, New York, NY,
in Healthcare: Archives
Southeastern Lowcountry
November 4-5, 2016.
April 1, 2016.
of Our Bodies, Ourselves.
Laura Rogers
American Society for
Rogers L. Public Archives,
and British Caribbean” in
School of Theology & Min-
American Indian Culture
Carroll M. Bloomsday
Michael Pittman
Bioethics and Humanities,
Shared Spaces: What
and Research Journal,
2016: Ulysses Unbound:
Travels in Gurdjieff’s Mi-
Washington, DC, October
Happens When Incarcer-
Volume 39, No. 3, 2015:
Readings and Ramblings.
lieu: Armenia and Turkey.
6-9, 2016 (paper presen-
ated Men Meet the “Incor-
148-149.
Irish American Heritage
All and Everything Human-
tation).
rigible Girls” of New York.
Museum, Albany, NY,
ities Conference, Salem,
June 2016.
MA, April 20-14, 2016
Kevin Hickey
Composition and Commu-
(Invited Presentation).
Jazzed Images – The
nication, Houston, TX,
Ornithological Arguments
April 6-9 2016.
B OOKS Kenneth Blume
Carroll M. Father Daniel
Historical Dictionary of
W. Cahill: The Irish Letters
U.S. Diplomacy from the Civil War to World War I,
Conference on College
of Jean-Michel Basquiat.
Home. American Con-
P O D I UM P RESE NTATIONS
41st Annual New York
Rogers L, Santicola T,
ference for Irish Studies,
Margaret Carroll
African Studies Associa-
Bogari K,Courtney K,
Rev. Ed. Rowman and
South Bend, IN, March
Carroll M. The Famine Irish
tion Conference on “Music
Kaley A, Pluckrose D,
Littlefield, 2016.
25-29, 2016.
in Albany, NY: Irish please
and the Arts of Africa
Olszewski K, Yehia A. If
44 AC P H S
PR ESI DENT’ S R EPORT SC HOLA RLY AC TIV ITY REPORT
You Try and Make Every
Conference, Keene, NH,
Pharmacists’ Union
HONORS AND
Organizer of 41st Annual
Paper Look the Same;
April 2-3, 2016.
of Greater New York.
APPOINTMENTS
New York African Studies
Researching New York
Tutors, Teachers, and Stu-
Association Conference
dents Explore the Grand
Daniel Smith
Conference, University at
Kevin Hickey
Narratives of Science
Smith D. Radical Politics
Albany, Albany, NY, No-
President of the New York
Writing. Northeast Writing
and Labor Organization:
vember 17-19, 2016 (Paper
African Studies Associa-
Center Association
Leon Davis and the
Presentation).
tion (current).
C E N T E R F O R I N N O VAT I V E L E A R N I N G PUBLICATIONS
Jennifer McVay-Dyche
Innovate Conference, New
Lewis KO, McVay-Dyche
Orleans, LA, April 2016.
2016.
Judy Teng
JM. Practical tools for
Doyle J, Teng J.
creating and sourcing
Fleming G, McVay-Dyche
A, Currie C. Instructional
Cyber-CYP: A Student
video-based lessons:
JM. The improved student
Design for Everyone.
Self-Directed Interactive
Screencasts and TED-
experience. Presentation
NorthEast Regional Com-
Animation Tool for Learn-
Ed. Workshop presented
at the Quality Matters Re-
puting Program, Affiliation
ing Cytochrome P450.
at the Online Learning
gional Conference, New
of EDUCAUSE, Worcester,
Proceedings of EdMedia:
Consortium’s Acceler-
York, NY, March 2016.
MA, November 2016
World Conference on
ate Conference, Lake
Educational Media and
Buena Vista, FL,
Judy Teng
Technology 2016 (pp.
November 2016.
Doyle J, Teng J.
O’Neil E, Teng J, Gauthier
(Invited Panelist).
Cyber-CYP: A Student
HONORS AND
for the Advancement of
Lewis KO, McVay-Dyche
Self-Directed Interactive
APPOINTMENTS
Computing in Education.
JM. One size does not
Animation Tool for Learn-
always fit all: How to tell
ing Cytochrome P450. Ed-
Tammy Garren
CONFERENCE
if your rubric works. Ex-
Media, World Conference
Garren T. 2016 MERLOT
PRESENTATIONS
press workshop presented
on Educational Media &
Peer Reviewer Extraordi-
at the Online Learning
Technology, Vancouver,
naire Award. The Multime-
Tammy Garren
Consortium’s Acceler-
BC, June 2016.
dia Educational Resource
Garren T, Skylstad K.
ate Conference, Orlando,
Flex Your Pedagogical
FL, November 2016.
Teng J. Instructional
Teaching (MERLOT), May
Muscles: Designing a Flex
McVay-Dyche JM,
Design Support for
2016.
Learning Module. Online
Tedesco L. Building the
Pharmacy Educators:
Learning Consortium
infrastructure for innova-
Project-Based Model
Accelerate International
tive collaborative course
and Beyond. American
Conference, Orlando, FL,
design and develop-
Association of Colleges
November 2016 (Pre-con-
ment. Education session
of Pharmacy Annual
ference workshop).
presented at the Online
Meeting, Anaheim, CA,
Learning Consortium’s In-
July 2016.
1624-1629), Association
for Learning and Online
Garren T, Obos L. Two-
novate Conference, New
Phase Pharmacy Skills
Orleans, LA, April 2016.
Zheng A, Feinberg D,
Student Reactions and Ef-
McVay-Dyche JM. Balanc-
ing a Regulatory Science
fect on Lab Performance.
ing act: Creating online
Course Blended with
American Association
videos that honor your
eLearning Lectures and
of Colleges of Pharma-
teaching style without
Active Learning. American
cy Annual Conference,
a full scale video produc-
Association of Pharma-
Anaheim, CA, July 2016
tion team. Information
ceutical Scientists Annual
(poster session).
session presented Online
Meeting and Exposition,
Learning Consortium’s
Denver, CO, November
Teng J. Design and Teach-
Laboratory Video Project:
(April 1-2, 2016).
S CH O LA R LY ACT IV IT Y R EP O RT AC P H S P RE SID E N T’ S RE P O RT 45
PHARMACEUTICAL RESEARCH INSTITUTE PUBLICATIONS P E E R RE V I E W E D A RT IC L E S
Brady SM, Shapiro L,
Solid Tumors 2016;6(1):
Muralidharan-Chari V,
LF, Chang HY, Tang HY,
Mousa SA. Current
65-77.
Kohan HG, Asimakopou-
Lin HY, Davis PJ. Novel
los AG, Sudha T, Sell S,
leptin OB3 peptide-in-
and future direction in the management of
Hercbergs A, Davis PJ, Lin
Kannan K, Boroujerdi
duced signaling and
Shaker A. Mousa
scleroderma. Archives of
HY, Mousa SA. Possible
M, Davis PJ, Mousa SA.
progression in thyroid
Abouelnaga A, Mutawa
Dermatological Research
contributions of thyroid
Microvesicle removal of
cancers: Comparison with
GA, Abdelghaffar H, Sobh
2016;308(7):461-471.
hormone replacement
anticancer drugs contrib-
leptin. Oncotarget 2016;
to specific behaviors
utes to drug resistance
7(19):27641-27654.
M, Hamed S, Mousa SA. Establishment and char-
Darwish NH, Sudha
of cancer. Biomedicine
in human pancreatic
acterization of primary hu-
T, Godugu K, Elbaz O,
& Pharmacotherapy
cancer cells. Oncotarget
Radak D, Katsiki N,
man ovarian cancer stem
Abdelghaffar HA, Hassan
2016;84:655-659.
2016;7(31):50365-50379.
Resanovic I, Jovanovic
cell line (CD44+ve). Jour-
EE, Mousa SA. Acute my-
nal of Cancer Research
eloid leukemia stem cell
Hsieh MT, Wang LM,
Muralidharan-Chari
Zafirovic S, Mousa SA,
Updates 2016;5(2).
markers in prognosis and
Changou CA, Chin YT,
V, Mousa SA. Heparin
Isenovic ER. Apoptosis
targeted therapy: Poten-
Yang YS, Lai HY, Lee SY,
neutralizer anticoagulant
and acute brain ischemia
Acheampong A, Mousa
tial impact of BMI-1, TIM-3
Yang YN, Whang-Peng
reversal agent. Drugs of
in ischemic stroke. Current
SA. Targeting strategies
and CLL-1. Oncotarget
J, Liu LF, Lin HY, Mousa
the Future 2016;41(6):341-
Vascular Pharmacology
of cancer stem cells in the
2016;7(36):57811-57820.
SA, Davis PJ. Crosstalk
346.
2016 Nov 3. [Epub ahead
A, Sudar-Milovanovic E,
of print].
between integrin αvβ3
management of solid tumors. Journal of Stem Cell
Davis PJ, Glinsky GV, Lin
and ERα contributes to
Rajabi M, Mousa SA. Lipid
Research and Transplan-
HY, Mousa SA. Actions
thyroid hormone-
nanoparticles and their
Zappa C, Mousa SA.
tation 2016;3(1):1023.
of thyroid hormone ana-
induced proliferation of
application in nanomed-
Non-small cell lung
logues on chemokines.
ovarian cancer cells.
icine. Current Pharma-
cancer: Current treatment
Alshaiban A, Muralidha-
Journal of Immunology
Oncotarget 2016:Jul 21.
ceutical Biotechnology
and future advances.
ran-Chari V, Nepo A,
Research 2016;3147671.
Apr 11 [Epub];8(15):24237-
2016;17(8):662-672.
Translational Lung Cancer Research 2016;5(3):288-
24249.
Mousa SA. Modulation of
Rajabi M, Sudha T, Dar-
300.
sickle red blood cell ad-
Della Badia LA, Elshour-
hesion and its associated
bagy NA, Mousa SA.
Lin HY, Chin YT, Nana
wish NH, Davis PJ, Mousa
changes in biomarkers
Targeting PCSK9 as a
AW, Shih YJ, Lai HY, Tang
SA. Synthesis of MR-49,
Zheng Y, Miao J, Zhang F,
by sulfated nonanticoag-
promising new mechanism
HY, Leinung M, Mousa
a deiodinated analog
Cai C, Koh A, Simmons TJ,
ulant heparin derivative.
for lowering low-density
SA, Davis PJ. Actions of
of tetraiodothyroacetic
Mousa SA, Linhardt RJ.
Clinical and Applied
lipoprotein cholesterol.
l-thyroxine and nano-di-
acid (tetrac), as a novel
Surface modification of a
Thrombosis and
Pharmacology & Thera-
amino-tetrac (nanotetrac)
pro-angiogenesis mod-
polyethylene film for anti-
Hemostasis
peutics 2016;164: 183-194.
on PD-L1 in cancer cells.
ulator. Bioorganic & Me-
coagulant and anti-mi-
Steroids 2016;114:59-67.
dicinal Chemistry Letters
crobial catheter. Reactive
2016;26(16):4112-4116.
and Functional Polymers
2016;22(3):230-238. ElFar AH, Shaheen HM,
2016;100:142-150.
Ardawi MS, Badawoud
ElDaim MA, Jaouni SKA,
Muralidharan-Chari
MH, Hassan SM, Rouzi
Mousa SA. Date palm
V, Kim J, Abuawad A,
Sahli ZT, Jo J, Mousa SA,
AA, Ardawi JM, AlNosani
(phoenix dactylifera):
Naeem M, Cui H, Mousa
Tarazi FI. Clinical man-
NM, Qari MH, Mousa
Protection and remedy
SA. Thymoquinone mod-
agement of restless legs
SA. Lycopene treatment
food. Current Trends in
ulates blood coagulation
syndrome in end-stage
Shaker A. Mousa
against loss of bone
Nutraceuticals 2016;1(2).
in vitro via its effects
renal disease patients.
Bowen N, Mousa SA.
on inflammatory and
CNS Spectrums 2016:1-8.
“Role of antiplatelet
mass, microarchitecture
BOOK CHAPTER S
therapy in neurosurgery:
and strength in relation to
Falcone R, Davis PJ,
coagulation pathways.
regulatory mechanisms
Stain SC, Mousa SA.
International Journal
Yang YC, Chin YT, Hsieh
Efficacy and safety
in a postmenopausal
Emerging therapies for
of Molecular Sciences
MT, Lai HY, Ke CC, Craw-
profiles” in Anticoagula-
osteoporosis model. Bone
pancreatic ductal
2016;17(4):474.
ford DR, Lee OK, Fu E,
tion and hemostasis in
2016;83: 127-140.
carcinoma. Journal of
Mousa SA, Grasso P, Liu
neurosurgery. Loftus CM,
46 AC P H S
PR ESI DENT’ S R EPORT SC HOLA RLY AC TIV ITY REPORT
ed. Switzerland: Springer;
Davis PJ, eds. Elsevier,
Davis PJ, Mousa SA.
Keynote Speaker. Al-
Appointed to Editorial
2016:65-89.
London: Academic Press;
“Tetraiodothyroacetic
ternative and Comple-
Board of Nanomedicine
2016:21-38.
acid at integrin αvβ3: A
mentary Medicines. King
and International Nano-
model of pharmaceutical
Abdulaziz University,
medicine.
El-Fawal HA, Rembisz R, Alobaidi R, Mousa SA.
Mousa SA, Muralidha-
anti-angiogenesis” in An-
Jeddah, Saudi Arabia,
“Chemotherapy-mediat-
ran-Chari V, Davis PJ.
ti-angiogenesis Strategies
April 4-8, 2016.
ed pain and peripheral
“Interface between throm-
in Cancer Therapies. Mou-
neuropathy: Impact of
bosis-inflammation and
sa SA, Davis PJ, eds. El-
Keynote Speaker. 6th
for Scientific Review
oxidative stress and
angiogenesis” in Anti-an-
sevier, London: Academic
Global Experts Meeting
Special Emphasis Panel
inflammation” in Oxidative
giogenesis Strategies in
Press; 2016:133-146.
& Expo on Nanomaterials
- ZRG1 F10A-S (20);
stress and antioxidant
Cancer Therapies. Mousa
and Nanotechnology
Fellowships: Physiology
protection: The science of
SA, Davis PJ, eds. Else-
Mousa SA, Sudha T, Davis
Congress and Expo.
and Pathobiology of
free radical biology and
vier, London: Academic
PJ. “Anti-angiogenesis
Dubai, United Arab Emir-
Cardiovascular and Re-
disease. Armstrong D,
Press; 2016:51-68.
therapy and its combina-
ates, April 21-23, 2016.
spiratory Systems, March
Stratton RD, eds. Hobo-
Appointed to NIH Study Section for Center
tion with chemotherapy:
10-11, 2016.
ken, NJ: John Wiley &
Davis PJ, Leinung M, Mou-
Impact on primary tumor
Keynote Speaker. World
Sons, Inc. 2016:367-388.
sa, SA. “MicroRNAs and
and its metastasis” in An-
Congress & Expo on Phar-
Appointed to NIH Study
angiogenesis” in Anti-an-
ti-angiogenesis Strategies
maceutics & Drug Deliv-
Section for Center for
Rajabi M, Srinivasan M,
giogenesis Strategies in
in Cancer Therapies. Mou-
ery Systems. Dubai, UAE,
Scientific Review Special
Mousa SA. “Nanobioma-
Cancer Therapies. Mousa
sa SA, Davis PJ, eds. El-
April 21-23, 2016.
Emphasis Panel - ZRG1
terials in drug delivery” in
SA, Davis PJ, eds. Else-
sevier, London: Academic
Nanobiomaterials in drug
vier, London: Academic
Press; 2016:147-163.
delivery. Grumezescu,
Press; 2016:69-84.
A, ed. William Andrew
CVRS-H (11 II); November Chair of Session on VTE
3-4, 2016.
in Cancer/Surgery. 24th Bharali DJ, Rajabi M,
International Congress
Appointed to NIH Study
Mousa SA, Abutaleb M,
Mousa SA. “Application of
on Thrombosis. Istanbul,
Section for Respiratory
Davis PJ. “Naturally oc-
nanotechnology to target
Turkey, May 4-7, 2016.
Sciences Small Business
Srinivasan M, Rajabi M,
curring anti-angiogenesis
tumor angiogenesis in
Mousa SA. “Nanobioma-
agents” in Anti-angiogen-
cancer therapeutics” in
Keynote speaker. 8th
Small Business Activities
terials in cancer therapy”
esis Strategies in Cancer
Anti-angiogenesis Strate-
World Medical Nanotech-
SEP [ZRG1 CVRS-H 11 B];
in Nanobiomaterials in
Therapies. Mousa SA,
gies in Cancer Therapies.
nology Congress. Dallas,
November 17-18, 2016.
cancer therapy. Gru-
Davis PJ, eds. Elsevier,
Mousa SA, Davis PJ, eds.
TX, June 9-11, 2016.
mezescu, A, ed.: William
London: Academic Press;
Elsevier, London: Academ-
Andrew Publishing;
2016:85-97.
ic Press; 2016:165-178.
International Drug Design
Shaker A. Mousa
Mousa SA, Darwish
Mousa SA, Davis PJ. “New
Congress. Istanbul, Tur-
Project: Tumor targeted
Shaker A. Mousa
NHE, Davis PJ. “Integrin
directions in anti-an-
key, October 13-15, 2016.
irradiation in mice
and Paul J. Davis
antagonists and angio-
giogenesis research”
Mousa SA, Davis, PJ. “An-
genesis” in Anti-angiogen-
in Anti-angiogenesis
Keynote Speaker. Special
ceuticals LLC
giogenesis and anti-an-
esis Strategies in Cancer
Strategies in Cancer
Session on Heparin
Total award: $30,720
giogenesis strategies in
Therapies. Mousa SA,
Therapies. Mousa SA,
Diversifications. Loyola
Period of Performance:
cancer” in Anti-angiogen-
Davis PJ, eds. Elsevier,
Davis PJ, eds. Elsevier,
University, Chicago, IL,
4/1/16 - 6/30/16
esis Strategies in Cancer
London: Academic Press;
London: Academic Press;
October 28, 2016.
Therapies. Mousa SA,
2016:99-123.
2016:179-186.
Publishing; 2016:1-37.
2016:57-89.
Davis PJ, eds. Elsevier,
- Respiratory Sciences
GRANTS Keynote speaker. 4th
Grantor: NanoPharma-
Project: Scale up N-DAT Keynote Speaker. Immi-
for Biological evaluation Grantor: NanoPharma-
London: Academic Press;
Davis PJ, Mousa SA.
LECTURES AND
grant Egyptian Oncology
2016:1-19.
“Tyrosine kinase inhibi-
KEYNOTES
Forum, Luxor, Egypt,
ceuticals LLC
December 14-16, 2016.
Total award: $78,080
tors and angiogenesis” Mousa SA, Yalcin M, Davis
in Anti-angiogenesis
Shaker A. Mousa
PJ. “Models for assessing
Strategies in Cancer
Plenary Lecture and
HONORS AND
anti-angiogenesis agents:
Therapies. Mousa SA,
Award of Excellence. 5th
APPOINTMENTS
Appraisal of current tech-
Davis PJ, eds. Elsevier,
Pan Arab Hematology
niques” in Anti-angiogen-
London: Academic Press;
Association Conference.
Shaker A. Mousa
Label the final Nano-di-
esis Strategies in Cancer
2016:125-131.
Cairo, Egypt, February
Appointed Editor-In-Chief
aminotetrac formulation
11-13, 2016.
of Biomedicines Journal
Grantor: NanoPharma-
Therapies. Mousa SA,
Period of Performance: 4/1/16 - 6/30/16 Project: Amendment to
S CHO LA R LY ACT IV IT Y R EP O RT AC P H S P RE SID E N T’ S RE P O RT 47
ceuticals LLC
Project: Scale up of C-TAT
mize the Loading for L-T3/
Total award: $74,240
and P-bi-TAT for Safety
NPs from 2% to 4%
Period of Performance:
Assessment in Male and
Grantor: Pro-Al Medico
5/1/16 - 10/31/16
Female Mice after Daily
(AGTT)
Exposure at Different
Total award: $66,000
Project: NDAT Process
Doses for 14 Days
Period of Performance:
Chemistry and Novel
Grantor: NanoPharma-
11/1/16 – 01/30/17
Derivatives
ceuticals LLC
Grantor: NanoPharma-
Total award: $89,872
ceuticals LLC
Period of Performance:
Total award: $40,960
09/19/16 - 3/31/17
Period of Performance: 4/1/16 - 6/30/16
Project: Analytical Method Development and
Project: NADT Backups
Pharmacokinetic Studies
Chemistry P-DAT
in Rodents
Grantor: NanoPharma-
Grantor: NanoPharma-
ceuticals LLC
ceuticals LLC
Total award: $61,440
Total award: $75,239
Period of Performance:
Period of Performance:
4/1/16 - 6/30/16
09/26/16 - 6/30/17
Project: Radiosensitiza-
Project: Synthesis and
tion of Pancreatic Cancer
Scale up /Test C-TAT
Grantor: NanoPharma-
against Neuroblastoma/
ceuticals LLC
Antiangiogenic study of
Total award: $122,880
C-TAT and P-bi-TAT vs
Period of Performance:
N-DAT and N-TAT
7/28/16 - 10/31/16
Grantor: NanoPharmaceuticals LLC
Project: Optimization of
Total award: $112,640
Lead clinical Candidate
Period of Performance:
and its anti-cancer effica-
11/28/16 - 6/30/17
cy versus Nano-DAT Identification of Lead
Project: A: Synthesis and
clinical Candidate(s)
scale up of β-C-TAT and
Polymer; Characteri-
Oral PK of β-C-TAT (IV/
zation of Lead Clinical
Oral PK), B: Test C-TAT
Candidate(s) in Crossing
(gamma-C-TAT, Subcuta-
the Blood Brain Barrier;
neous and β-C-TAT, Oral)
Anti-Cancer Efficacy of
Grantor: NanoPharma-
Lead clinical Candi-
ceuticals LLC
date(s) Polymer; and An-
Total award: $112,641
ti-Cancer Efficacy of Lead
Period of Performance:
clinical Candidate(s)
11/28/16-4/30/17
Polymer conjugated Non-Nano DAT or TAT
Project: Service Agree-
derivatives
ment for additional
Grantor: NanoPharma-
work on Amendment of
ceuticals LLC
Synthesis of 10 grams
Total award: $122,880
L-T3 nanoformulations
Period of Performance:
(PLGA-T3 NPs) – Develop
7/28/16 - 6/30/17
L-T3-PLGA NPs coated with Chitosan, 2- Opti-
48 ACP H S
PR ESI DENT’ S R EPORT
FINANCIAL REPORT J U LY 1 , 2 0 1 5 – J U N E 3 0 , 2 0 1 6
STATEMENT OF FINANCIAL POSITION
A SSE TS Cash and cash equivalents___________________ $27,413,499 Investments________________________________ 45,689,914 Other assets________________________________ 1,562,094 Accounts receivable - Students, net_______________ 633,461 Receivables - Government entities, net_____________ 444,200 Pledges receivable___________________________ 1,785,086
TOTA L A S S E TS
Student loan receivable_______________________2,484,854 Other receivables_____________________________ 400,824 Assets held in charitable remainder annuity trust_____ 154,463 Agency funds_________________________________348,174
TOTA L LI A BI LI TI E S
Property, plant & equipment, net________________ 45,621,641 TOTA L A SSE TS ____________________ $ 1 26 , 5 3 8 , 21 0 L IA B IL IT IE S Accounts payable and accrued liabilities_________ $2,013,735
N E T A S S E TS
Deferred income and deposits__________________ 7,203,328 U.S. government grants refundable_______________ 2,367,539 Bonds payable____________________________ 23,456,428 Expected post retirement benefit obligation_______ 2,339,552 Other liabilities______________________________ 1,042,397 Deposits held in custody for others_________________348,174 TOTA L L IA B IL IT IE S_____________________ $ 3 8 ,771 ,1 5 3 NE T A SSE TS
R EV EN U ES
Unrestricted net assets______________________$74,439,659 Temporarily restricted net assets________________ $4,939,168 EXPENSES
Permanently restricted net assets______________ $8,388,230 TOTA L NE T A SSE TS __________________ $ 8 7,76 7, 0 5 7 TOTA L L IA B IL IT IE S A ND NE T A SSE TS _ $ 1 26 , 5 3 8 , 21 0
STATEMENT OF ACTIVITIES
REVENUES
E XP E NSE S
Student tuition and fees, net of financial aid__________ 78.92%
Instruction/Student services_______________________ 44.15%
Auxiliary enterprises_____________________________ 9.33%
Physical plant_________________________________ 25.97%
Government contracts and grants___________________ 4.16%
General administration__________________________ 18.56%
Gifts and pledges_______________________________ 2.91%
Research______________________________________ 5.78%
Investment income______________________________2.04%
Institutional advancement_________________________2.63%
Other sources__________________________________2.26%
Student financial aid_____________________________2.05%
Postgraduate education__________________________ 0.38%
Postgraduate education__________________________0.86%
TOTA L_______________________________________ 1 0 0 %
TOTA L ____________________________________ 1 0 0 %
B OA R D O F TR U S TE E S OFFICERS Marion Morton, ’84, Chair Matthew Bette, Vice Chair Christopher D. Mitiguy, Treasurer Kandyce J. Daley, ’74, Secretary TERM TRUSTEES Stephen Ainlay Raymond Bleser Jr., ’81 Walter S. Borisenok Leigh Briscoe-Dwyer, ’87 Richard H. Daffner, ’63 Thomas D’Ambra James E. Dering Paul DerOhannesian II Chris Di Lascia, ’83 Michael Duteau, ’92 Geno J. Germano, ’83 Rocco Giruzzi, ’58 Susan Learned, ’91 James Notaro, ’84 David Stack, ‘76 Scott Terrillion, ’85 Pamela Williamson
PU B LI S H E D AU G U S T 2 0 1 7 E D I TO R Gil Chorbajian PHOTOGRAPHY Kris Qua DESIGN 2COMMUNIQUÉ
NON-PROFIT ORG. U.S. POSTAGE
PAID PERMIT #349 ALBANY, NY
ALBANY COLLEGE OF PHARMACY A N D H E A LT H S C I E N C E S 106 NEW SCOTLAND AVENUE ALBANY, NY 12208 WWW.ACPHS.EDU